Amphastar Pharmaceuticals (AMPH) 10-Q 9 Nov 16 2016 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 02, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Amphastar Pharmaceuticals, Inc.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	1,297,184
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Entity Common Stock, Shares Outstanding		46,023,798

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current Assets:
Cash and Cash Equivalents, at Carrying Value	$ 66,598	$ 66,074
Short-term investments	856
Restricted short-term investments	1,390	1,285
Accounts receivable, net	26,550	33,233
Inventories, net	90,650	70,665
Income tax refund and deposits	159	238
Prepaid expenses and other assets	3,983	4,439
Total current assets	190,186	175,934
Property, plant, and equipment, net	151,952	142,161
Goodwill and intangible assets, net	51,732	39,901
Other assets	7,544	4,696
Deferred tax assets	27,423	27,444
Total assets	428,837	390,136
Current Liabilities:
Accounts payable	13,439	13,872
Accrued liabilities	14,695	16,732
Income taxes payable	6,210	3,076
Accrued payroll and related benefits	15,553	12,840
Current portion of product return accrual	1,569	1,858
Current portion of deferred revenue	830	643
Current portion of long-term debt and capital leases	8,541	10,934
Total current liabilities	60,837	59,955
Long-term product return accrual	1,137	763
Long-term reserve for income tax liabilities	497	497
Long-term deferred revenue	168	1,339
Long-term debt and capital leases, net of current portion	34,163	30,165
Long-term deferred tax liabilities	1,616
Other long-term liabilities	1,966	1,907
Total liabilities	100,384	94,626
Stockholders’ equity:
Preferred stock: par value $.0001; authorized shares—20,000,000; no shares issued and outstanding
Common stock: par value $.0001; authorized shares—300,000,000; issued and outstanding shares—47,506,416 and 46,038,022 at September 30, 2016 and 45,960,206 and 45,198,491 at December 31, 2015, respectively	5	5
Additional paid-in capital	276,543	247,829
Retained earnings	73,597	60,323
Accumulated other comprehensive loss	(2,581)	(2,475)
Treasury stock	(19,111)	(10,172)
Total stockholders’ equity	328,453	295,510
Total liabilities and stockholders’ equity	$ 428,837	$ 390,136

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
CONDENSED CONSOLIDATED BALANCE SHEETS
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock; authorized shares	300,000,000	300,000,000
Common stock; shares issued	47,506,416	45,960,206
Common stock; outstanding shares	46,038,022	45,198,491

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Net revenues	$ 64,223	$ 63,868	$ 191,622	$ 174,607
Cost of revenues	36,611	46,290	107,394	130,431
Gross profit	27,612	17,578	84,228	44,176
Operating expenses:
Selling, distribution, and marketing	1,291	1,171	3,975	4,163
General and administrative	10,801	9,034	31,129	32,793
Research and development	9,723	11,117	28,591	28,411
Impairment of long-lived assets		4	331	78
Total operating expenses	21,815	21,326	64,026	65,445
Income (loss) from operations	5,797	(3,748)	20,202	(21,269)
Non-operating income (expense):
Interest income	63	83	187	240
Interest expense	(281)	(232)	(970)	(783)
Other income (expense), net	422	(379)	150	1,110
Total non-operating income (expense), net	204	(528)	(633)	567
Income (loss) before income taxes	6,001	(4,276)	19,569	(20,702)
Income tax expense (benefit)	2,111	(1,268)	6,295	(10,382)
Net income (loss)	$ 3,890	$ (3,008)	$ 13,274	$ (10,320)
Net income (loss) per share:
Basic (in Dollars per share)	$ 0.09	$ (0.07)	$ 0.29	$ (0.23)
Diluted (in Dollars per share)	$ 0.08	$ (0.07)	$ 0.29	$ (0.23)
Weighted-average shares used to compute net income (loss) per share:
Basic (in Shares)	45,398	45,310	45,132	44,920
Weighted Average Number of Shares Outstanding, Diluted	47,953	45,310	46,365	44,920

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Net income (loss)	$ 3,890	$ (3,008)	$ 13,274	$ (10,320)
Accumulated other comprehensive income (loss)
Foreign currency translation adjustment	109	374	(106)	(2,106)
Total accumulated other comprehensive income (loss)	109	374	(106)	(2,106)
Total comprehensive income (loss)	$ 3,999	$ (2,634)	$ 13,168	$ (12,426)

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash Flows From Operating Activities:
Net income (loss)	$ 13,274	$ (10,320)
Reconciliation to net cash provided by operating activities:
Impairment of long-lived assets	331	78
Loss on disposal of property, plant, and equipment	663	19
Depreciation of property, plant, and equipment	9,009	8,516
Amortization of product rights, trademarks, and patents	1,751	1,458
Imputed interest accretion	55	83
Employee share-based compensation expense	10,482	8,687
Non-employee share-based compensation expense	1,122	670
Reserve for income tax liabilities		16
Changes in deferred taxes		(3,541)
Changes in operating assets and liabilities:
Accounts receivable, net	6,756	(2,706)
Inventories, net	(19,477)	8,549
Income tax refund and deposits	3,112	21
Prepaid expenses and other assets	173	(6,516)
Income taxes payable	103	(1,083)
Accounts payable and accrued liabilities	(2,800)	3,463
Net cash provided by operating activities	24,554	7,394
Cash Flows From Investing Activities:
Acquisition of business	(12,461)
Purchases of property, plant, and equipment	(14,457)	(10,685)
Capitalized labor, overhead, and interest on self-constructed assets	(1,588)	(1,242)
Proceeds from the sale of property, plant and equipment		51
Purchase of short-term investments	(2,270)
Maturity of short-term investments	1,414
Decrease (increase) in restricted cash	(105)	210
Payment of deposits and other assets	(2,921)	(800)
Net cash used in investing activities	(32,388)	(12,466)
Cash Flows From Financing Activities:
Repurchase of common stock	(1,342)	(857)
Net proceeds from equity plans	18,499	11,539
Payments on treasury stock	(8,986)	(5,687)
Proceeds from issuance of long-term debt	10,198	6,786
Principal payments on long-term debt	(9,968)	(3,973)
Net cash provided by financing activities	8,401	7,808
Effect of exchange rate changes on cash	(43)	117
Net increase in cash and cash equivalents	524	2,853
Cash and cash equivalents at beginning of period	66,074	67,828
Cash and cash equivalents at end of period	66,598	70,681
Noncash Investing and Financing Activities:
Equipment acquired under capital leases	1,263	150
Supplemental Disclosures of Cash Flow Information:
Interest paid	1,381	1,345
Income taxes paid	$ 3,263	$ 45

General

General	9 Months Ended
	Sep. 30, 2016
General
General	1. Genera Amphastar Pharmaceuticals, Inc., a California corporation, was incorporated on February 29, 1996, and merged with and into Amphastar Pharmaceuticals, Inc., a Delaware corporation, in July 2004 (together with its subsidiaries, hereinafter referred to as “the Company”). The Company is a specialty pharmaceutical company that primarily develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products including products with high technical barriers to market entry. Additionally, the Company sells insulin active pharmaceutical ingredient, or API products. Most of the Company’s products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company’s insulin API products are sold to other pharmaceutical companies for use in their own products and are being used by the Company in the development of injectable finished pharmaceutical products. The Company’s inhalation products will be primarily distributed through drug retailers once they are brought to market. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2015, and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission, or the SEC. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles, or GAAP, have been condensed or omitted from the accompanying condensed consolidated financial statements. The accompanying year-end condensed consolidated balance sheet was derived from the audited financial statements. The accompanying interim financial statements are unaudited, but reflect all adjustments which are, in the opinion of management, necessary for a fair statement of the Company’s condensed consolidated financial position, results of operations, comprehensive income (loss) and cash flows for the periods presented. Unless otherwise noted, all such adjustments are of a normal, recurring nature. The Company’s results of operations, comprehensive income (loss) and cash flows for the interim periods are not necessarily indicative of the results of operations and cash flows that it may achieve in future periods.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2016
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation All significant intercompany activity has been eliminated in the preparation of the condensed consolidated financial statements. The unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of Form 10-Q and Rule 10-01 of Regulation S-X. Some information and footnote disclosures normally included in financial statements prepared in accordance with GAAP, have been condensed or omitted pursuant to those rules and regulations. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the condensed consolidated financial position, results of operations, and cash flows of the Company. The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: International Medication Systems, Limited, or IMS; Armstrong Pharmaceuticals, Inc., or Armstrong; Amphastar Nanjing Pharmaceuticals Co., Ltd., or ANP; Nanjing Letop Fine Chemistry Co., Ltd., or Letop, Amphastar France Pharmaceuticals, S.A.S., or AFP, Amphastar UK Ltd., or AUK, and International Medication Systems (UK) Limited, or IMS UK. Use of Estimates The preparation of the condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The principal accounting estimates include: determination of allowances for doubtful accounts and discounts, provision for chargebacks, liabilities for product returns, reserves for excess or unsellable inventory, impairment of long-lived and intangible assets and goodwill, self-insured claims, workers’ compensation liabilities, litigation reserves, stock price volatilities for share-based compensation expense, valuation allowances for deferred tax assets, and liabilities for uncertain income tax positions. Foreign Currency The functional currency of the Company, its Chinese subsidiary, ANP, and its U.K. subsidiary, AUK, is the U.S. dollar, or USD. ANP maintains its books of record in Chinese Yuan. These books are remeasured into the functional currency of USD using the current or historical exchange rates. The resulting currency remeasurement adjustments and other transactional foreign currency exchange gains and losses are reflected in the Company’s statements of operations. The Company’s French subsidiary, AFP, Chinese subsidiary, Letop, and U.K. subsidiary, IMS UK, maintain their books of record in Euros, Chinese Yuan, and Great Britain Pounds, respectively, which are the local currencies and have been determined to be their respective functional currencies. These books are translated into USD using average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transactions. Translation adjustments are reflected in stockholders’ equity and are included as a component of other comprehensive income (loss). The gains or losses of intercompany foreign currency transactions that are of a long-term investment nature are reported in other comprehensive income (loss). The gains and losses of intercompany foreign currency transactions for the three and nine months ended September 30, 2016 were a $0.3 million gain and a $0.6 million gain, respectively, and for the three and nine months ended September 30, 2015 were a $0.3 million gain and a $1.6 million loss, respectively. Additionally, the Company does not undertake hedging transactions to cover its foreign currency exposure. Comprehensive Income (Loss) For the three and nine months ended September 30, 2016 and 2015, the Company included its foreign currency translation adjustment as part of its comprehensive income (loss). Financial Instruments The carrying amounts of cash and cash equivalents, short-term investments, restricted short-term investments, accounts receivable, accounts payable, accrued expenses, and short-term borrowings approximate fair value due to the short maturity of these items. A majority of the Company’s long-term obligations consist of variable rate debt, and their carrying value approximates fair value as the stated borrowing rates are comparable to rates currently offered to the Company for instruments with similar maturities. However, the Company has one fixed-rate, long-term mortgage for which the carrying value differs from the fair value and is not remeasured on a recurring basis (see Note 12). Deferred Income Taxes The Company utilizes the liability method of accounting for income taxes, under which deferred taxes are determined based on the temporary differences between the financial statements and the tax basis of assets and liabilities using enacted tax rates. A valuation allowance is recorded when it is more likely than not that the deferred tax assets will not be realized. The Company has adopted the with-and-without methodology for determining when excess tax benefits from the exercise of share‑based awards are realized. Under the with-and-without methodology, current year operating loss deductions and prior-year operating loss carryforwards are deemed to be utilized prior to the utilization of current-year excess tax benefits from share‑based awards. Business Combinations Business combinations are accounted for in accordance with Accounting Standards Codification, or ASC 805, Business Combinations, using the acquisition method of accounting, which requires an acquirer to recognize the assets acquired and the liabilities assumed at the acquisition date measured at their fair values as of that date. Fair value determinations are based on discounted cash flow analyses or other valuation techniques. In determining the fair value of the assets acquired and liabilities assumed in a material acquisition, the Company may utilize appraisals from third party valuation firms to determine fair values of some or all of the assets acquired and liabilities assumed, or may complete some or all of the valuations internally. In either case, the Company takes full responsibility for the determination of the fair value of the assets acquired and liabilities assumed. The value of goodwill reflects the excess of the fair value of the consideration conveyed to the seller over the fair value of the net assets received. Acquisition-related costs that the Company incurs to effect a business combination are expensed in the periods in which the costs are incurred. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board, or FASB, issued an accounting standards update that creates a single source of revenue guidance for companies in all industries. The new standard provides guidance for all revenue arising from contracts with customers and affects all entities that enter into contracts to provide goods or services to their customers, unless the contracts are within the scope of other accounting standards. It also provides a model for the measurement and recognition of gains and losses on the sale of certain nonfinancial assets. This guidance must be adopted using either a full retrospective approach for all periods presented or a modified retrospective approach and will be effective for fiscal years beginning after December 15, 2017, which will be the Company’s fiscal 2018. The Company has not yet evaluated the potential impact of adopting the guidance on the Company’s condensed consolidated financial statements. In August 2014, the FASB issued an accounting standards update that will require management to evaluate if there is substantial doubt about the Company’s ability to continue as a going concern and, if so, to disclose this in both interim and annual reporting periods. This guidance will become effective for the Company’s annual filing for the period ending December 31, 2016, and interim reporting periods thereafter, and allows for early adoption. The Company does not expect the adoption of the guidance will have a material impact on the Company’s condensed consolidated financial statements. In July 2015, the FASB issued an accounting standards update which requires entities to measure most inventories at the lower of cost or net realizable value, or NRV, thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market. Under the new guidance, inventory is measured at the lower of cost or net realizable value, which eliminates the need to determine replacement cost and evaluate whether it is above the ceiling (NRV) or below the floor (NRV less a normal profit margin). The guidance defines NRV as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for annual periods beginning after December 15, 2016, and interim reporting periods therein. The standard will be effective for the Company for the first quarter of the Company’s fiscal 2017. Early application is permitted. The new guidance must be applied prospectively. The Company does not believe the adoption of this accounting guidance will have a material impact on the Company’s condensed consolidated financial statements and related disclosures. In November 2015, the FASB issued an accounting standards update to the balance sheet classification of deferred taxes. Under existing standards, deferred taxes for each tax-paying jurisdiction are presented as a net current asset or liability and net long-term asset or liability. To simplify presentation, the new guidance will require that all deferred tax assets and liabilities, along with related valuation allowances, be classified as long-term on the balance sheet. As a result, each tax-paying jurisdiction will now only have one net long-term deferred tax asset or liability. The new guidance does not change the existing requirement that prohibits offsetting deferred tax liabilities from one jurisdiction against deferred tax assets of another jurisdiction. The guidance is effective for annual periods beginning after December 15, 2016, and interim reporting periods therein. Early adoption is permitted. The new guidance may be applied prospectively or retrospectively. The Company has elected to adopt the guidance early and apply the guidance prospectively. Therefore, prior periods were not retrospectively adjusted. The reclassification of the Company’s deferred tax assets and liabilities does not have any impact on the Company’s net income or cash flow; thus, the adoption of the guidance does not have a material impact on the Company’s condensed consolidated financial statements. In February 2016, the FASB issued an accounting standards update that is aimed at making leasing activities more transparent and comparable, and which requires substantially all leases to be recognized by lessees on their balance sheets as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. This guidance will become effective for the Company’s interim and annual reporting periods during the year ending December 31, 2019, and all annual and interim reporting periods thereafter. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its condensed consolidated financial statements and related disclosures. In March 2016, the FASB issued an accounting standards update that is aimed at improving the employee share-based payment accounting. The standard update simplifies the accounting for employee share-based payments and involves several aspects of the accounting for share-based transactions, including the potential timing of expenses, the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The guidance is effective for annual periods beginning after December 15, 2016, and interim reporting periods therein. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its condensed consolidated financial statements and related disclosures. In June 2016, the FASB issued an accounting standards update that is aimed at providing financial statement users with more useful information about the expected credit losses on financial instruments and other commitments to extend credit. The standard update changes the impairment model for financial assets measured at amortized cost, requiring presentation at the net amount expected to be collected. The measurement of expected credit losses requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Available-for-sale debt securities with unrealized losses will be recorded through an allowance for credit losses. The guidance is effective for the Company’s interim and annual reporting periods during the year ending December 31, 2020. The Company is currently evaluating the impact that the adoption of this guidance will have on its condensed consolidated financial statements and related disclosures. In August 2016, the FASB issued an accounting standards update that is aimed at addressing certain issues regarding classifications of certain cash receipt and cash payment on the statement of cash flows where diversity in practice was identified. The guidance is effective for the Company’s interim and annual reporting periods during the year ending December 31, 2018. Early adoption is permitted. The Company does not believe that the adoption of this accounting guidance will have a material impact on the Company’s condensed consolidated financial statements and related disclosures.

Business Acquisitions

Business Acquisitions	9 Months Ended
	Sep. 30, 2016
Business Acquisitions
Business Acquisitions	3. Business Acquisitions Acquisition of International Medication Systems (UK) Limited from UCB PHARMA GmbH In August 2016, the Company’s newly established UK subsidiary, AUK, acquired IMS UK, a UK-based subsidiary of UCB PHARMA GmbH, including its trademarks, assets related to the products, as well as marketing authorizations for 33 products in the UK, Ireland, Australia, and New Zealand, representing 11 different injectable chemical entities. The Company paid $7.7 million in cash as consideration for the transaction. The Company plans to transfer the manufacturing of the purchased products to its facilities in California. The transfer will require approval of the UK Medicines and Healthcare products Regulatory Agency and other related regulatory agencies before the products can be sold by the Company. The transaction is accounted for as a business combination in accordance with ASC 805. The Company’s accounting for this acquisition is preliminary specifically related to the fair value estimation of identified intangible assets. The fair values of the assets acquired and liabilities assumed include marketing authorizations of $9.2 million, manufacturing equipment of $0.1 million, and deferred tax liability of $1.6 million. The acquired marketing authorizations intangible assets are subject to a straight-line amortization over a useful life of approximately 10 years. The Company’s estimates and assumptions are subject to change as the Company obtains additional information for its estimates during the measurement period (up to one year from the acquisition date). Acquisition of fourteen injectable products from Hikma Pharmaceuticals PLC In March 2016, the Company acquired 14 abbreviated new drug applications, or ANDAs, representing 11 different injectable chemical entities from Hikma Pharmaceuticals PLC for $4.0 million. The Company plans to transfer the manufacturing of these products to its facilities in California, which will require U.S. Food & Drug Administration, or FDA approval before the products can be launched. The Company has concluded that this transaction will be accounted for as a business combination in accordance with ASC 805. The Company’s accounting for this acquisition is preliminary specifically related to the fair value estimation of identified intangible assets. The ANDA is estimated to have a fair value of $4.0 million, which is subject to a straight-line amortization over a useful life of approximately 15 years. The Company’s estimates and assumptions are subject to change as the Company obtains additional information for its estimates during the measurement period (up to one year from the acquisition date). Acquisition of Nanjing Letop Medical Technology Co. Ltd. In January 2016, the Company’s Chinese subsidiary, ANP, acquired Nanjing Letop Medical Technology Co. Ltd. for $1.7 million consisting of $0.8 million in cash and a deposit of $0.9 million that ANP had previously paid to Letop and which was effectively eliminated upon the consummation of the transaction. The Company accounted for this transaction as a business combination in accordance with ASC 805. The Company recognized $1.4 million of acquired assets, $0.1 million of assumed liabilities, and $0.4 million of goodwill. Letop had previously supplied ANP with intermediates used in making various active pharmaceutical ingredients. In March 2016, the acquired subsidiary was renamed Nanjing Letop Fine Chemistry Co., Ltd. Acquisition of Merck’s API Manufacturing Business On April 30, 2014, the Company completed its acquisition of the Merck Sharpe & Dohme’s API manufacturing business in Éragny-sur-Epte, France, or the Merck API Transaction, which manufactures porcine insulin API and recombinant human insulin API, or RHI API. The purchase price of the transaction totaled €24.8 million, or $34.4 million on April 30, 2014, subject to certain customary post‑closing adjustments and currency exchange rate fluctuations. The terms of the purchase include multiple payments over four years as follows (see Note 12): U.S. Euros Dollars (in thousands) At Closing, April 2014 € $ December 2014 December 2015 December 2016 December 2017 € $ In order to facilitate the acquisition, the Company established AFP in France. The Company is continuing the current site manufacturing activities, which consist of the manufacturing of porcine insulin API and RHI API. As part of the transaction, the Company has entered into various additional agreements, including various supply agreements, as well as the assignment and/or licensing of patents under which Merck was operating at this facility. In addition, certain existing customer agreements have been assigned to AFP.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2016
Revenue Recognition
Revenue Recognition	4. Revenue Recognition Generally, revenue is recognized at the time of product delivery to the Company’s customers. In some cases, revenue is recognized at the time of shipment when stipulated by the terms of the sale agreements. The Company also records profit-sharing revenue stemming from a distribution agreement with Actavis, Inc., or Actavis. This distribution agreement is in the process of being terminated (see Note 16). Profit-sharing revenue is recognized at the time Actavis sells the products to its customers. Revenues derived from contract manufacturing services are recognized when third-party products are shipped to customers, after the customer has accepted test samples of the products to be shipped. The Company does not recognize product revenue unless the following fundamental criteria are met: (i) persuasive evidence that an arrangement exists, (ii) transfer of title has occurred, (iii) the price to the customer is fixed or determinable, and (iv) collection is reasonably assured. Furthermore, the Company does not recognize revenue until all customer acceptance requirements have been met. The Company estimates and records reductions to revenue for discounts, product returns, and pricing adjustments, such as wholesaler chargebacks, in the same period that the related revenue is recorded. The Company’s accounting policy is to review each agreement involving contract development and manufacturing services to determine if there are multiple revenue-generating activities that constitute more than one unit of accounting. Revenues are recognized for each unit of accounting based on revenue recognition criteria relevant to that unit. The Company does not have any revenue arrangements with multiple deliverables. Provision for Wholesaler Chargebacks The provision for chargebacks is a significant estimate used in the recognition of revenue. As part of its sales terms with wholesale customers, the Company agrees to reimburse wholesalers for differences between the gross sales prices at which the Company sells its products to wholesalers and the actual prices of such products at the time wholesalers resell them under the Company’s various contractual arrangements with third parties such as hospitals and group purchasing organizations. The Company estimates chargebacks at the time of sale to wholesalers based on wholesaler inventory stocking levels, historic chargeback rates, and current contract pricing. The provision for chargebacks is reflected in net revenues and a reduction to accounts receivable. The following table is an analysis of the chargeback provision: Nine Months Ended September 30, 2016 2015 (in thousands) Beginning balance $ $ Provision related to sales made in the current period Credits issued to third parties Ending balance $ $ Changes in chargeback provision from period to period are primarily dependent on the Company’s sales to its wholesalers, the level of inventory held by the wholesalers, and on the wholesaler’s customer mix. The approach that the Company uses to estimate chargebacks has been consistently applied for all periods presented. Variations in estimates have been historically small. The Company continually monitors the provision for chargebacks and makes adjustments when it believes that the actual chargebacks may differ from the estimates. The settlement of chargebacks generally occurs within 30 days after the sale to wholesalers. Accrual for Product Returns The Company offers most customers the right to return qualified excess or expired inventory for partial credit; however, products sold to Actavis are non-returnable. The Company’s product returns primarily consist of the returns of expired products from sales made in prior periods. Returned products cannot be resold. At the time product revenue is recognized, the Company records an accrual for estimated returns. The accrual is based, in part, upon the historical relationship of product returns to sales and customer contract terms. The Company also assesses other factors that could affect product returns including market conditions, product obsolescence, and the introduction of new competition. Although these factors do not normally give the Company’s customers the right to return products outside of the regular return policy, the Company realizes that such factors could ultimately lead to increased returns. The Company analyzes these situations on a case-by-case basis and makes adjustments to the product return reserve as appropriate. The provision for product returns is reflected in net revenues. The following table is an analysis of product return liability: Nine Months Ended September 30, 2016 2015 (in thousands) Beginning balance $ $ Provision for product returns Credits issued to third parties Ending balance $ $ For the nine months ended September 30, 2016 and 2015 , the Company’s aggregate product return rate was 1.1% and 1.1% of qualified sales, respectively.

Income (Loss) per Share

Income (Loss) per Share	9 Months Ended
	Sep. 30, 2016
Income (Loss) per Share
Income (Loss) per Share	5. Income (loss) per Share Basic income (loss) per share is calculated based upon the weighted-average number of shares outstanding during the period. Diluted income per share gives effect to all potential dilutive shares outstanding during the period, such as stock options, nonvested deferred stock units and restricted stock units (collectively referred to herein as “RSUs”), and shares issuable under the Company’s Employee Stock Purchase Plan, or the ESPP. For the three months ended September 30, 2016, options to purchase 1,357,154 shares of stock with a weighted-average exercise price of $29.31 per share, were excluded in the computation of diluted net income per share because the effect from the assumed exercise of these options would be anti-dilutive. For the nine months ended September 30, 2016, options to purchase 4,510,729 shares of stock with a weighted-average exercise price of $19.84 per share, were excluded in the computation of diluted net income per share because the effect from the assumed exercise of these options would be anti-dilutive. As the Company reported a net loss for the three and nine months ended September 30, 2015, the diluted net loss per share, as reported, is equal to the basic net loss per share since the effect of the assumed exercise of stock options, vesting of nonvested RSUs, and issuance of common shares under the ESPP are anti-dilutive. Total shares excluded from the three and nine months ended September 30, 2015, net loss per share were 12,471,789 stock options, 877,665 nonvested RSUs, and 165,167 shares issuable under the ESPP. The following table provides the calculation of basic and diluted net income (loss) per share for each of the periods presented: Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 (in thousands, except per share data) Basic and dilutive numerator: Net income (loss) $ $ $ $ Denominator: Weighted-average shares outstanding — basic Net effect of dilutive securities: Incremental shares from equity awards — — Weighted-average shares outstanding — diluted Net income (loss) per share — basic $ $ $ $ Net income (loss) per share — diluted $ $ $ $

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2016
Segment Reporting
Segment Reporting	6. Segment Reporting The Company’s business is the development, manufacture, and marketing of pharmaceutical products. The Company has established two reporting segments that each report to the Chief Operating Decision Maker, or CODM, as defined in ASC 280, Segment Reporting. The Company’s performance is assessed and resources are allocated by the CODM based on the following two reportable segments: · Finished pharmaceutical products · Active pharmaceutical ingredients, or API The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn ® , Amphadase ® , naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI and porcine insulin. The Company also uses RHI for internal product development. Selected financial information by reporting segment is presented below: Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 (in thousands) Net revenues: Finished pharmaceutical products $ $ $ $ API Total net revenues Gross profit: Finished pharmaceutical products API Total gross profit Operating expenses Income (loss) from operations Non-operating income (expenses) Income (loss) before income taxes $ $ $ $ The Company manages its business segments to the gross profit level and manages its operating and other costs on a company-wide basis. The Company does not identify total assets by segment for internal purposes, as the Company’s CODM does not assess performance, make strategic decisions, or allocate resources based on assets. Prior to the Merck API Transaction on April 30, 2014, Merck notified the Company of several environmental items that were not in alignment with Merck’s internal policies and procedures. None of these items were in violation of any French environmental law or regulation. The Company has assessed the nature of the remedial actions to be undertaken and since April 30, 2014, recorded the related expenses of €0.6 million as incurred in cost of sales within the API segment. Based on the letter of understanding signed in conjunction with the acquisition on April 30, 2014, the Company and Merck further entered into an agreement on May 11, 2016, pursuant to which Merck shall reimburse the Company for the costs to complete the remedial actions up to €6.0 million. Accordingly, in the nine months ended September 30, 2016, the Company recorded the reimbursement of €0.6 million for the expenses already incurred as a reduction of cost of sales within the API segment. The amount of net revenues in the finished pharmaceutical products segment is presented below: Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 (in thousands) Finished pharmaceutical products net revenues: Enoxaparin $ $ $ $ Naloxone Lidocaine Phytonadione Epinephrine Other finished pharmaceutical products Total finished pharmaceutical products net revenues $ $ $ $ Net revenues and carrying values of long-lived assets of enterprises by geographic regions are as follows: Net Revenue Long-Lived Assets Three Months Ended Nine Months Ended September 30, September 30, September 30, December 31, 2016 2015 2016 2015 2016 2015 (in thousands) United States $ $ $ $ $ $ China — — — — France United Kingdom — — — — — Total $ $ $ $ $ $

Customer and Supplier Concentra

Customer and Supplier Concentration	9 Months Ended
	Sep. 30, 2016
Customer and Supplier Concentration
Customer and Supplier Concentration	7. Customer and Supplier Concentration Customer Concentrations Three large wholesale drug distributors, AmerisourceBergen Corporation, or AmerisourceBergen, Cardinal Health, Inc. or Cardinal Health, and McKesson Corporation, or McKesson, are all distributors of the Company’s products, as well as suppliers of a broad range of health care products. Actavis had exclusive marketing rights of the Company’s enoxaparin product to the U.S. retail pharmacy market (see Note 16). MannKind Corporation began buying RHI API from the Company in December 2014. The Company considers these five customers to be its major customers, as each individually, and these customers collectively, represented a significant percentage of the Company’s net revenue for the three and nine months ended September 30, 2016 and 2015, and accounts receivable as of September 30, 2016 and December 31, 2015. The following table provides accounts receivable and net revenues information for these major customers: % of Total Accounts % of Net Receivable Revenue Three Months Ended Nine Months Ended September 30, December 31, September 30, September 30, 2016 2015 2016 2015 2016 2015 Actavis (1) % % % % % % AmerisourceBergen % % % % % % Cardinal Health % % % % % % MannKind Corporation % % % % % % McKesson % % % % % % (1) Effective June 30, 2016, the Company and Actavis agreed to terminate the agreement upon the earlier of (i) January 1, 2017, and (ii) such earlier date that is 30 days after Actavis notifies the Company in writing that Actavis has less than 30 days inventory of the enoxaparin product remaining in its possession or scheduled to be delivered pursuant to the pending purchase orders (see Note 16). Supplier Concentrations The Company depends on suppliers for raw materials, active pharmaceutical ingredients, and other components that are subject to stringent FDA requirements. Some of these materials may only be available from one or a limited number of sources. Establishing additional or replacement suppliers for these materials may take a substantial amount of time, as suppliers must be approved by the FDA. Furthermore, a significant portion of raw materials may only be available from foreign sources. If the Company is unable to secure, on a timely basis, sufficient quantities of the materials that it depends on to manufacture and market its products, it could have a material adverse effect on the Company’s business, financial condition, and results of operations.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2016
Fair Value Measurements
Fair Value Measurements	8. Fair Value Measurements The accounting standards of the FASB define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal or most advantageous market for the asset or liability at the measurement date (an exit price). These standards also establish a hierarchy that prioritizes observable and unobservable inputs used in measuring fair value of an asset or liability, as described below: · Level 1 – Inputs to measure fair value are based on quoted prices (unadjusted) in active markets on identical assets or liabilities; · Level 2 – Inputs to measure fair value are based on the following: a) quoted prices in active markets on similar assets or liabilities, b) quoted prices for identical or similar instruments in inactive markets, or c) observable (other than quoted prices) or collaborated observable market data used in a pricing model from which the fair value is derived; and · Level 3 – Inputs to measure fair value are unobservable and the assets or liabilities have little, if any, market activity; these inputs reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities based on the best information available in the circumstances. The Company measures fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company classifies its cash equivalents and restricted short-term investments as Level 1 assets, as they are valued on a recurring basis using quoted market prices with no valuation adjustments applied. The Company does not hold any Level 2 or Level 3 instruments that are measured for fair value on a recurring basis. The fair values of the Company’s financial assets and liabilities measured on a recurring basis, as of September 30, 2016 and December 31, 2015, are as follows: Quoted Prices in Active Markets Significant Other Significant Other for Identical Observable Unobservable Assets Inputs Inputs Total (Level 1) (Level 2) (Level 3) (in thousands) Cash equivalents $ $ $ — $ — Restricted short-term investments — — Fair value measurement as of September 30, 2016 $ $ $ — $ — Cash equivalents $ $ $ — $ — Restricted short-term investments — — Fair value measurement as of December 31, 2015 $ $ $ — $ — The fair value of the Company’s cash equivalents includes money market accounts, money market funds, Money Market Insured Deposit Account Service and Insured Cash Sweep accounts. Restricted short-term investments consist of certificate of deposit accounts that expire within 12 months for which market prices are readily available. The restrictions placed on the certificate of deposit accounts have a negligible effect on the fair value of these financial assets; these funds are restricted to meet the Company’s obligation for workers’ compensation claims. Short-term investments primarily consist of held-to-maturity municipal bonds with original maturities greater than three months. The municipal bonds are carried at amortized cost in the Company’s consolidated balance sheet, which approximates their fair value determined based on Level 2 inputs. The Company does not intend to and will not be required to sell the investments before recovery of their amortized cost basis. The Company adopted the required fair value measurements and disclosures provisions related to nonfinancial assets and liabilities. These assets and liabilities are not measured at fair value on a recurring basis but are subject to fair value adjustments in certain circumstances. These items primarily include long-lived assets, goodwill, and intangible assets for which the fair value of assets is determined as part of the related impairment test. As of September 30, 2016 and December 31, 2015, there were no significant adjustments to fair value for nonfinancial assets or liabilities.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets
Goodwill and Intangible Assets	9. Goodwill and Intangible Assets The table below shows the weighted-average life, original cost, accumulated amortization, and net book value by major intangible asset classification as of the dates set forth below: Weighted-Average Accumulated Life (Years) Original Cost Amortization Net Book Value (in thousands) Definite-lived intangible assets Product rights 12 $ $ $ Acquired international product rights (1) 10 Acquired ANDAs (2) 15 Patents 10 Land-use rights 39 Other intangible assets 1 Subtotal 12 Indefinite-lived intangible assets Trademark * — Goodwill Finished pharmaceutical products * — Subtotal * — As of September 30, 2016 * $ $ $ * (1) In August 2016, the Company acquired International Medication Systems (UK) Limited from UCB PHARMA GmbH for $7.7 million. The fair value of the marketing authorization was $9.2 million as of the acquisition date. The accounting for this transaction is preliminary (see Note 3). (2) In March 2016, the Company acquired 14 ANDAs representing 11 different injectable chemical entities from Hikma Pharmaceuticals PLC for $4.0 million. The accounting for this transaction is preliminary (see Note 3). Weighted-Average Accumulated Life (Years) Original Cost Amortization Net Book Value (in thousands) Definite-lived intangible assets Product rights 12 $ $ $ Patents 10 Land-use rights 39 Other intangible assets 1 Subtotal 12 Indefinite-lived intangible assets Trademark * — Goodwill Finished pharmaceutical products * — Subtotal * — As of December 31, 2015 * $ $ $ * Intangible assets with indefinite lives have an indeterminable average life. Goodwill The changes in the carrying amounts of goodwill were as follows: September 30, December 31, 2016 2015 (in thousands) Beginning balance $ $ Goodwill related to acquisition of business — Currency translation and other adjustments Ending balance $ $ Primatene ® Trademark In January 2009, the Company acquired the exclusive rights to the trademark, domain name, website and domestic marketing, distribution and selling rights related to Primatene ® Mist, an over-the-counter bronchodilator product, for a total consideration of $29.2 million, which is its carrying value as of September 30, 2016. In determining the useful life of the trademark, the Company considered the following: the expected use of the intangible; the longevity of the brand; the legal, regulatory and contractual provisions that affect their maximum useful life; the Company’s ability to renew or extend the asset’s legal or contractual life without substantial costs; effects of the regulatory environment; expected changes in distribution channels; maintenance expenditures required to obtain the expected future cash flows from the asset; and considerations for obsolescence, demand, competition and other economic factors. As a result of environmental concerns about Chlorofluorocarbons, or CFCs, the FDA issued a final ruling on January 16, 2009, that required the CFC formulation of its Primatene ® Mist product to be phased out by December 31, 2011. The former formulation of Primatene ® Mist contained CFCs as a propellant; however, the Company intends to use the trademark for a future version of Primatene ® that utilizes hydrofluoroalkane, or HFA, as a propellant. In 2013, the Company filed a new drug application, or NDA, for Primatene ® Mist and received a Prescription Drug User Fee Act date set for May 2014. In May 2014, the Company received a complete response letter, or CRL, from the FDA, which required additional non-clinical information, label revisions and follow-up studies (label comprehension, behavioral/human factors and actual use) to assess consumers’ ability to use the device correctly to support approval of the product in the over-the-counter setting. The Company met with the FDA in October 2014 to discuss preliminary data results and to clarify the FDA requirements for further studies. The Company received further advice regarding its ongoing studies from the FDA in January 2016, and subsequently completed the human factor studies accordingly. The Company submitted the NDA amendment on June 28, 2016 and received a target response date of December 28, 2016. However, there can be no guarantee that any amendment to the Company’s NDA will result in timely approval of Primatene ® Mist, or approval at all. Based on the Company’s filed version of Primatene ® Mist, the Company’s response to the CRL to address the FDA’s concerns, the long history of the Primatene ® trademark (marketed since 1963) and the Company’s perpetual rights to the trademark, the Company has determined that the trademark has an indefinite useful life. If the HFA version is approved by the FDA, it will be marketed under the same trade name; therefore, an impairment charge would not be required.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2016
Inventories
Inventories	10. Inventories Inventories are stated at the lower of cost or market, using the first-in, first-out method. Provisions are made for slow-moving, unsellable or obsolete items. Inventories consist of the following: September 30, December 31, 2016 2015 (in thousands) Raw materials and supplies $ $ Work in process Finished goods Total inventory Less reserve for excess and obsolete inventories Total inventory, net $ $

Property, Plant, and Equipment

Property, Plant, and Equipment	9 Months Ended
	Sep. 30, 2016
Property, Plant, and Equipment
Property, Plant, and Equipment	11. Property, Plant, and Equipment Property, plant, and equipment consist of the following: September 30, December 31, 2016 2015 (in thousands) Buildings $ $ Leasehold improvements Land Machinery and equipment Furniture, fixtures, and automobiles Construction in progress Total property, plant, and equipment Less accumulated depreciation Total property, plant, and equipment, net $ $ As of September 30, 2016, the Company had $2.6 million in capitalized manufacturing equipment that is intended to be used specifically for the manufacture of Primatene ® Mist. The Company will continue to monitor developments with the FDA as it relates to its Primatene ® indefinite lived intangible asset in determining if there is an impairment of these related fixed assets (see Note 9).

Debt

Debt	9 Months Ended
	Sep. 30, 2016
Debt
Debt	12. Debt Debt consists of the following: September 30, December 31, 2016 2015 (in thousands) Loans with East West Bank Mortgage payable matured January 2016 $ — $ Mortgage payable matured September 2016 — Equipment loan due April 2017 Line of credit facility due September 2017 — — Equipment loan due January 2019 Mortgage payable due February 2021 — Equipment credit line due September 2021 — Mortgage payable due October 2026 — Loans with Cathay Bank Line of credit facility due May 2018 — — Acquisition loan due April 2019 Mortgage payable due April 2021 Loans with Seine-Normandie Water Agency French government loan 1 due March 2018 French government loan 2 due June 2020 French government loan 3 due July 2021 Payment Obligation to Merck Equipment under Capital Leases Total debt and capital leases Less current portion of long-term debt and capital leases Long-term debt and capital leases, net of current portion $ $ Loans with East West Bank Equipment Loan—Due April 2017 In March 2012, the Company entered into an $8.0 million revolving credit facility. In March 2013, the Company converted the outstanding principal balance of $4.9 million into an equipment loan, which matures in April 2017. Borrowings under the facility are secured by equipment purchased with debt proceeds. Borrowings under the facility bear a variable interest rate at the prime rate as published by The Wall Street Journal , plus 0.25%, with a minimum interest rate of 3.50%. As of September 30, 2016, the fair value of the loan approximates its book value. The interest rate used in the fair value estimation was determined to be a Level 2 input. Line of Credit Facility—Due September 2017 In March 2012, the Company entered into a $10.0 million line of credit facility. Borrowings under the facility are secured by inventory and accounts receivable. Borrowings under the facility bear a variable interest rate at the prime rate as published by The Wall Street Journal . This facility matured in March 2016. In March 2016, the Company amended the facility to increase the line of credit to $15.0 million and extended the maturity date to September 2017. As of September 30, 2016, the Company did not have any amounts outstanding under this facility. Equipment Loan—Due January 2019 In July 2013, the Company entered into an $8.0 million line of credit facility. Borrowings under the facility were secured by equipment. The facility bore a variable interest rate at the prime rate as published in The Wall Street Journal plus 0.25% and was to mature in January 2019. In January 2015, the Company drew down $6.2 million from the line of credit facility. Subsequently, the facility was converted into an equipment loan with an outstanding principal balance of $6.2 million and a maturity date of January 2019. Borrowings under the facility are secured by the equipment purchased with the debt proceeds. The Company entered into a fixed interest rate swap contract on this facility to exchange the variable interest rate for a fixed interest rate of 4.48% over the life of the facility without the exchange of the underlying notional debt amount. The fair value of the derivative and unrealized loss was immaterial to the Company’s condensed consolidated financial statement at September 30, 2016. As of September 30, 2016, the fair value of the loan approximates its book value. The interest rate used in the fair value estimation was determined to be a Level 2 input. Mortgage Payable—Due February 2021 In December 2010, the Company refinanced an existing mortgage term loan, which had an outstanding principal balance of $4.5 million at December 31, 2010. The loan was payable in monthly installments with a final balloon payment of $3.8 million. The loan was secured by one of the buildings at the Company’s Rancho Cucamonga, California, headquarters complex, as well as one of its buildings at its Chino, California, complex. The loan had a variable interest rate at the prime rate as published by The Wall Street Journal, with a minimum interest rate of 5.00%, and matured in January 2016. The Company refinanced the existing mortgage term loan in January 2016, which had an outstanding principal balance of $3.7 million at December 31, 2015, and a maturity date of February 2021. The refinanced loan is payable in monthly installments with a final balloon payment of $3.3 million. The refinanced loan is secured by one of the buildings at the Company’s Rancho Cucamonga, California, headquarters complex. The refinanced loan has a variable interest rate at the prime rate as published by The Wall Street Journal . Subsequently, the Company entered into a fixed interest rate swap contract on this loan to exchange the variable interest rate for a fixed interest rate of 4.39% over the life of the loan without the exchange of the underlying notional debt amount. The fair value of the derivative and unrealized loss was approximately $0.1 million at September 30, 2016. As of September 30, 2016, the fair value of the loan approximates its book value. The interest rate used in the fair value estimation was determined to be a Level 2 input. Equipment Credit Line–Due September 2021 In March 2016, the Company entered into a $5.0 million equipment credit line with an 18-month draw down period and interest payments due monthly through September 2017 at the prime rate as published by The Wall Street Journal . After the draw down period, the outstanding principal balance converts into a 48-month loan with principal and interest payments due monthly. Borrowings under the facility are secured by the equipment purchased with the debt proceeds, and bear a variable interest rate at the prime rate as published by The Wall Street Journal . This facility matures in September 2021. As of September 30, 2016, the fair value of the loan approximates its book value. The interest rate used in the fair value estimation was determined to be a Level 2 input. As of September 30, 2016, the Company has drawn $2.9 million from the equipment line of credit. Mortgage Payable—Due October 2026 In September 2006, the Company entered into a mortgage term loan in the principal amount of $2.8 million, which matured in September 2016. The loan was payable in monthly installments with a final balloon payment of $2.2 million plus interest. The loan was secured by one of the buildings at the Company’s Rancho Cucamonga, California, headquarters complex. The variable interest rate was equal to the three-month LIBOR plus 2.50%. The Company refinanced the existing mortgage term loan in September 2016, which increased the principal amount to $3.6 million and extended the maturity date to October 2026. The refinanced loan is payable in monthly installments with a final balloon payment of $2.9 million. The refinanced loan has a variable interest rate at the one-month LIBOR rate plus 2.75%. Subsequently, the Company entered into a fixed interest rate swap contract on this loan to exchange the variable interest rate for a fixed interest rate of 4.15% until October 2021 without the exchange of the underlying notional debt amount. The fair value of the derivative and the unrealized loss was approximately $0.1 million at September 30, 2016. As of September 30, 2016, the fair value of the loan approximates its book value. The interest rate used in the fair value estimation was determined to be a Level 2 input. Loans with Cathay Bank Line of Credit Facility—Due May 2018 In April 2012, the Company entered into a $20.0 million revolving line of credit facility. Borrowings under the facility are secured by inventory, accounts receivable, and intangibles held by the Company. The facility bears a variable interest rate at the prime rate as published by The Wall Street Journal with a minimum interest rate of 4.00%. This revolving line of credit was to mature in May 2016. In June 2016, the Company modified the facility to extend the maturity date to May 2018. As of September 30, 2016, the Company did not have any amounts outstanding under this facility. Acquisition Loan with Cathay Bank—Due April 2019 On April 22, 2014, in conjunction with the Merck API Transaction, the Company entered into a secured term loan with Cathay Bank as lender. The principal amount of the loan is $21.9 million and bears a variable interest rate at the prime rate as published by The Wall Street Journal , with a minimum interest rate of 4.00%. Beginning on June 1, 2014, and through the maturity date, April 22, 2019, the Company must make monthly payments of principal and interest based on the then outstanding amount of the loan amortized over a 120‑month period. On April 22, 2019, all amounts outstanding under the loan become due and payable, which would be approximately $12.0 million based upon an interest rate of 4.00%. The loan is secured by 65% of the issued and outstanding shares of stock in AFP and certain assets of the Company, including accounts receivable, inventory, certain investment property, goods, deposit accounts, and general intangibles but not including the Company’s equipment and real property. As of September 30, 2016, the fair value of the loan approximates its book value. The interest rate used in the fair value estimation was determined to be a Level 2 input. The loan includes customary restrictions on, among other things, the Company’s ability to incur additional indebtedness, pay dividends in cash or make other distributions in cash, make certain investments, create liens, sell assets, and make loans. The loan also includes customary events of defaults, the occurrence and continuation of any of which provide Cathay Bank the right to exercise remedies against the Company and the collateral securing the loan. These events of default include, among other things, the Company’s failure to pay any amounts due under the loan, the Company’s insolvency, the occurrence of any default under certain other indebtedness or material agreements, and a final judgment against the Company that is not discharged in 30 days. Mortgage Payable—Due April 2021 In March 2007, the Company entered into a mortgage term loan in the principal amount of $5.3 million, which matured in March 2014. In April 2014, the Company refinanced the mortgage term loan, which had an outstanding principal balance of $4.6 million. The loan is payable in monthly installments with a final balloon payment of $3.9 million. The loan is secured by the building at the Company’s Canton, Massachusetts location, bears interest at a fixed rate of 5.42%, and matures in April 2021. As of September 30, 2016, the fair value of the loan approximates its book value. The interest rate used in the fair value estimation was determined to be a Level 2 input. Loans with Seine-Normandie Water Agency In January 2015, the Company entered into three French government loans with the Seine-Normandie water agency in the aggregate amount of €0.6 million, or $0.7 million, subject to currency exchange rate fluctuations. The life of the loans ranges between three to six years, includes annual equal payments and bears no interest over the life of the loans. As of September 30, 2016, the payment obligation had an aggregate book value of €0.4 million, or $0.4 million, subject to currency exchange rate fluctuations, which approximates fair value. The fair value of the payment obligation was determined by using the interest rate associated with the Company’s acquisition loan with Cathay Bank that bears a variable interest rate at the prime rate as published by The Wall Street Journal , with a minimum interest rate of 4.00%. Such interest rate is deemed to be a Level 2 input for measuring fair value. Payment Obligation to Merck Merck—Due December 2017 On April 30, 2014, in conjunction with the Merck API Transaction, the Company entered into a commitment obligation with Merck, in the principal amount of €11.6 million, or $16.0 million, subject to currency exchange rate fluctuations. The terms of the purchase price include annual payments over four years and bear a fixed interest rate of 3.00%. The final payment to Merck relating to this obligation is due December 2017. In December 2015 and 2014, the Company made a principal payment of €3.2 million, or $3.5 million and €4.9 million, or $6.0 million, respectively. As of September 30, 2016, the payment obligation had a book value of €3.6 million, or $4.1 million, which approximates fair value. The fair value of the payment obligation was determined by using the interest rate associated with the Company’s acquisition loan with Cathay Bank that bears a variable interest rate at the prime rate as published by The Wall Street Journal , with a minimum interest rate of 4.00%. Such interest rate is deemed to be a Level 2 input for measuring fair value. Covenants At September 30, 2016 and December 31, 2015, the Company was in compliance with its debt covenants, which include a minimum current ratio, minimum debt service coverage, minimum tangible net worth, and maximum debt-to-effective-tangible-net-worth ratio, computed on a consolidated basis in some instances and on a separate-company basis in others. Equipment under Capital Leases The Company entered into leases for certain equipment under capital leasing arrangements, which will expire at various times through 2021. The cost of equipment under capital leases was $2.0 million and $1.5 million at September 30, 2016 and December 31, 2015, respectively. The accumulated depreciation of equipment under capital leases was $0.1 million and $0.7 million at September 30, 2016 and December 31, 2015, respectively. Depreciation of assets recorded under capital leases is included in depreciation expense in the accompanying condensed consolidated financial statements.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2016
Income Taxes
Income Taxes	13. Income Taxes The following table sets forth the Company’s income tax provision for the periods indicated: Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 (in thousands) Income (loss) before taxes $ $ $ $ Income tax expense (benefit) Net income (loss) $ $ $ $ Income tax provision (benefit) as a percentage of income (loss) before income taxes % % % % The Company’s income tax provision for the three and nine months ended September 30, 2016, was 35.2% and 32.2% of income before taxes, respectively. The Company has a full valuation allowance against its French deferred tax assets; however, a tax benefit is included in the annual effective tax rate computation due to the French entity reporting a year-to-date foreign exchange gain in other comprehensive income. The blended effective income tax rate expected for the year ending December 31, 2016, is 32.4%. This effective tax rate factors in various permanent differences, including domestic deductions, the impact of foreign operations, and various credits. The Company’s income tax benefit of 29.7% and 50.1% during the three and nine months ended September 30, 2015, respectively, factored in similar permanent items, as well as the impact of its foreign operations. Valuation Allowance In assessing the need for a valuation allowance, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. Ultimately, the realization of deferred tax assets depends on the existence of future taxable income. M anagement considers sources of taxable income such as income in prior carryback periods, future reversal of existing deferred taxable temporary differences, tax-planning strategies, and projected future taxable income. In connection with the AFP purchase accounting in 2014, the Company recorded a valuation allowance against a deferred tax asset of €3.2 million, or $4.4 million, subject to currency exchange rate fluctuations, with an offsetting entry to goodwill, since management did not believe that it was more likely than not that the deferred tax asset would be realized. In March 2015, the Company reversed the €3.2 million, or $3.3 million, subject to currency exchange rate fluctuations, deferred tax valuation allowance in conjunction with the transfer of AFP’s intangible assets from France to the United States. The difference in U.S. dollars relates to the currency exchange rate fluctuation, which is recorded in the Company’s accumulated other comprehensive loss as a foreign currency translation adjustment. In 2015, the Company assessed the realizability of the deferred tax assets for AFP. Due to the potential impact of reduced revenues from the MannKind contract and other factors, the Company determined that it was not more likely than not that the net deferred tax assets of AFP would be realized. Therefore, the Company established a full valuation allowance of $0.9 million as of December 31, 2015, and continues to maintain a full valuation allowance on all AFP deferred tax assets. In 2016, for computing its annual effective tax rate, the Company did not benefit from its losses in the states where it files separately. This had no material impact on the Company’s income tax expense during the three months ended September 30, 2016, and increased the Company’s income tax expense by $0.2 million during the nine months ended September 30, 2016.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2016
Stockholders' Equity
Stockholders' Equity	14. Stockholders' Equity A summary of the changes in stockholders’ equity for the nine months ended September 30, 2016, consisted of the following: Nine Months Ended September 30, 2016 (in thousands) Stockholders’ equity as of December 31, 2015 $ Net income Accumulated other comprehensive loss Exercise of stock options Issuance of common stock to employees under the ESPP Nonemployee share-based compensation expense Employee share-based compensation expense Repurchase of common stock (1) Purchase of treasury stock Stockholders’ equity as of September 30, 2016 $ (1) Repurchase of common stock relating to the tax withholding of equity award settlements. 2014 Employee Stock Purchase Plan In June 2014, the Company adopted the ESPP in connection with its initial public offering. A total of 2,000,000 shares of common stock are reserved for issuance under this plan. The Company’s ESPP permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. Under the ESPP, the Company may specify offerings with durations of not more than 27 months, and may specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of its common stock will be purchased for employees participating in the offering. An offering may be terminated under certain circumstances. The price at which the stock is purchased is equal to 85% of the lower of the fair market value of the common stock at the beginning of an offering period or on the date of purchase. As of September 30, 2016, the Company has issued 193,849 shares of common stock under the ESPP and 1,806,151 shares of its common stock remain available for issuance. For the three and nine months ended September 30, 2016 , the Company recorded ESPP expense of $0.1 million and $0.4 million, respectively . For the three and nine months ended September 30, 2015 , the Company recorded ESPP expense of $0.1 million and $0.4 million, respectively . Share Buyback Program On November 6, 2014, the Company’s Board of Directors authorized a $10.0 million share buyback program, which was completed in December 2015. On November 10, 2015, the Company’s Board of Directors authorized an additional $10.0 million share buyback program. The primary goal of the programs is to offset dilution created by the Company’s equity compensation programs. Purchases are being made through the open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions or other means as determined by the Company’s management and in accordance with the requirements of the SEC. The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions. These repurchased shares are accounted for under the cost method and are included as a component of treasury stock in the Company’s consolidated balance sheets. Pursuant to the Company’s share repurchase program, the Company purchased 46,333 and 710,833 shares of its common stock during the three and nine months ended September 30, 2016, for total consideration of $0.8 million and $9.0 million, respectively. The 2015 Equity Incentive Plan In March 2015, the Board of Directors adopted the Company’s 2015 Equity Incentive Plan, or the 2015 Plan, which was approved by the Company’s stockholders in May 2015 and is set to expire in March 2025. The 2015 Plan is designed to meet the needs of a publicly traded company, including the requirements for granting “performance based compensation” under Section 162(m) of the Internal Revenue Code. The 2015 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units, performance shares, and other stock or cash awards to employees of the Company and its subsidiaries, members of the Board of Directors and consultants. The Company initially reserved 5,000,000 shares of common stock for issuance under the 2015 Plan. This number will be increased by the number of shares available for issuance under the Company’s prior equity incentive plans or arrangements that are not subject to options or other awards, plus the number of shares of common stock related to options or other awards granted under the Company’s prior equity incentive plans or arrangements that are repurchased, forfeited, expired, or cancelled on or after the effective date of the 2015 Plan. The 2015 Plan also contains an “evergreen provision” that allows for an annual increase in the number of shares available for issuance on January 1 of each year during the 10 year term of the 2015 Plan, beginning January 1, 2016. The annual increase in the number of shares shall be the lesser of (i) 3,000,000 shares, (ii) two and one-half percent (2.5%) of the outstanding shares on the last day of the immediately preceding fiscal year, or (iii) such number of shares as determined by the Board of Directors. As of the effective date, there were 5,300,296 shares available for grant under the 2015 Plan. As of September 30, 2016, the Company reserved an aggregate of 3,938,687 shares of common stock for future issuance under the 2015 Plan, including an additional 1,129,962 shares reserved under the 2015 Plan pursuant to the evergreen provision. Share-Based Award Activity and Balances Stock Options The fair value of option awards made to employees and directors is estimated at the grant date using the Black-Scholes pricing model and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period using the straight-line method. The weighted-averages for key assumptions used in determining the fair value of options granted during the three and nine months ended September 30, 2016 and 2015, are as follows: Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Average volatility % % % % Risk-free interest rate % % % % Weighted-average expected life in years Dividend yield rate — % — % — % — % A summary of option activity under all plans for the nine months ended September 30, 2016, is presented below: Weighted-Average Weighted-Average Remaining Aggregate Exercise Contractual Intrinsic Options Price Term (Years) Value (1) (in thousands) Outstanding as of December 31, 2015 $ Options granted Options exercised Options cancelled Options expired Outstanding as of September 30, 2016 $ $ Exercisable as of September 30, 2016 $ $ (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the estimated fair value of the Company’s common stock for those awards that have an exercise price below the estimated fair value at September 30, 2016. For the three and nine months ended September 30, 2016 , the Company recorded stock option expense related to employees and the Board of Directors under all plans of $1 .9 million and $6 .7 million, respectively. For the three and nine months ended September 30, 2015 , the Company recorded stock option expense related to employees and the Board of Directors under all plans of $2.1 million and $6.1 million, respectively. Information relating to option grants and exercises is as follows: Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 (in thousands, except per share data) Weighted-average grant date fair value $ $ $ $ Intrinsic value of options exercised Cash received Total fair value of the options vested during the year A summary of the status of the Company’s nonvested options as of September 30, 2016 and changes during the nine months ended September 30, 2016 is presented below: Weighted-Average Grant Date Options Fair Value Nonvested as of December 31, 2015 $ Options granted Options vested Options forfeited Nonvested as of September 30, 2016 As of September 30, 2016, there was $12.5 million of total unrecognized compensation cost, net of forfeitures, related to nonvested stock option based compensation arrangements granted under all plans. The cost is expected to be recognized over a weighted-average period of 2.3 years and will be adjusted for future changes in estimated forfeitures. Deferred Stock Units/Restricted Stock Units Beginning in 2007, the Company granted deferred stock units, or DSUs, to certain employees and members of the Board of Directors with a vesting period of up to five years, and commencing in 2015, such equity was issued as restricted stock units, or RSUs (such RSUs and DSUs are collectively referred to as RSUs). The grantee receives one share of common stock at a specified future date for each RSU awarded. The RSUs may not be sold or otherwise transferred until certificates of common stock have been issued, recorded, and delivered to the participant. The RSUs do not have any voting or dividend rights prior to the issuance of certificates of the underlying common stock. The share-based expense associated with these grants was based on the Company’s common stock fair value at the time of grant and is amortized over the requisite service period, which generally is the vesting period, using the straight-line method. The Company recorded a total expense of $1.5 million and $4.5 million for the three and nine months ended September 30, 2016, respectively, for these RSU awards compared to the prior year expense of $1.1 million and $2.8 million for the three and nine months ended September 30, 2015, respectively . As of September 30, 2016, there was $11.4 million of total unrecognized compensation cost, net of forfeitures, related to nonvested RSU-based compensation arrangements granted under all Plans. The cost is expected to be recognized over a weighted-average period of 2.4 years and will be adjusted for future changes in estimated forfeitures. Information relating to RSU grants and deliveries is as follows: Total Fair Market Value of RSUs Issued Total RSUs as Issued Compensation (1) (in thousands) RSUs outstanding at December 31, 2015 RSUs granted $ RSUs forfeited Common stock delivered RSUs surrendered for taxes RSUs outstanding at September 30, 2016 (1) The total fair market value is derived from the number of RSUs granted times the current stock price on the date of grant. Equity Awards to Consultants The Company has entered into various consulting agreements with its stockholders and third-party consultants. Consulting expenses are accrued as services are rendered. Consulting services are paid in cash and/or in common stock or stock options of the Company. Share-based compensation expense is recorded over the service period based on the estimated fair value of the equity award at the date services are performed or upon completion of all services under the agreement. During the three months ended September 30, 2016, the Company recorded an immaterial amount of share-based compensation related to the issuance of equity awards for services rendered by consultants. During the nine months ended September 30, 2016, the Company recorded approximately $0.1 million, in share-based compensation related to the issuance of equity awards for services rendered by consultants. During the three and nine months ended September 30, 2015, the Company recorded approximately $0.1 million and $0.1 million, respectively, in share-based compensation related to the issuance of equity awards for services rendered by consultants. The Company recorded share-based compensation expense under all plans and it is included in the Company’s consolidated statement of operations as follows: Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 (in thousands) Cost of revenues $ $ $ $ Operating expenses: Selling, distribution, and marketing General and administrative Research and development Total share-based compensation $ $ $ $

Employee Benefits

Employee Benefits	9 Months Ended
	Sep. 30, 2016
Employee Benefits
Employee Benefits	15. Employee Benefits 401(k) Plan The Company has a defined contribution 401(k) plan, or the Plan, whereby eligible employees voluntarily contribute up to a defined percentage of their annual compensation. The Company matches contributions at a rate of 50% on the first 6% of employee contributions, and pays the administrative costs of the Plan. Employer contributions vest over four years. Total employer contributions for the three and nine months ended September 30, 2016, were approximately $0.3 million and $0.7 million, respectively, compared to the prior year expense of $0.2 million and $0.5 million for the three and nine months ended September 30, 2015, respectively. Defined Benefit Pension Plan In connection with the Merck API Transaction, the Company assumed an obligation associated with a defined-benefit plan for eligible employees of AFP. This plan provides benefits to the employees from the date of retirement and is based on the employee’s length of time with the Company. The calculation is based on a statistical calculation combining a number of factors that include the employee’s age, length of service, and AFPs turnover rate. The liability under the plan is based on a discount rate of 1.75% as of September 30, 2016 and December 31, 2015. The liability is included in accrued liabilities in the accompanying consolidated balance sheets. The plan is currently unfunded, and the benefit obligation under the plan was $1.7 million and $1.6 million at September 30, 2016 and December 31, 2015, respectively. The Company recorded an immaterial amount of expense under the plan for the three months ended September 30, 2016, and $0.1 million for the nine months ended September 30, 2016. The Company recorded an immaterial amount of expense under the plan for the three months ended September 30, 2015, and $0.1 million for the nine months ended September 30, 2015.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies
Commitments and Contingencies	16. Commitments and Contingencies Distribution Agreement with Actavis, Inc. In May 2005, the Company entered into an agreement to grant certain exclusive marketing rights for its enoxaparin product to Andrx Pharmaceuticals, Inc., or Andrx, which generally extends to the U.S. retail pharmacy market. To obtain such rights, Andrx made a non-refundable, upfront payment of $4.5 million to the Company upon execution of the agreement, which was classified as deferred revenues. Under the agreement, the Company is to be paid a fixed cost per unit sold to Andrx and also shares in the gross profits (as defined) from Andrx’s sales of the enoxaparin product in the U.S. retail pharmacy market. In November 2006, Watson Pharmaceuticals, Inc., or Watson, acquired Andrx and all of the rights and obligations associated with the agreement. In January 2013, Watson adopted Actavis, Inc. as its new global name. In March 2015, Actavis acquired Allergan plc and adopted Allergan plc as its new global name in June 2015. In January 2012, the Company launched its enoxaparin product, beginning the seven-year period during which Actavis has the exclusive marketing rights for the Company’s enoxaparin product in the U.S. retail pharmacy market and the start of the Company’s recognition of the $4.5 million deferred revenue over this period on a straight-line basis. Actavis has an option to renew the agreement for an additional three years. As of June 30, 2016 and December 31, 2015, the balance of the deferred revenue was $1.7 million and $2.0 million, respectively. On June 30, 2016, the Company and Actavis agreed to terminate the agreement upon the earlier of (i) January 1, 2017, and (ii) such earlier date that is 30 days after Actavis notifies the Company in writing that Actavis has less than 30 days inventory of the enoxaparin product remaining in its possession or scheduled to be delivered pursuant to the pending purchase orders. The Company recognizes the remaining balance of the deferred revenue over the period from July 1, 2016 through December 31, 2016, on a straight-line basis as a result of the revised estimate of the contractual period. As of September 30, 2016, the balance of the deferred revenue was $0.8 million. The Company manufactures its enoxaparin product for the retail market according to demand specifications of Actavis. Upon shipment of enoxaparin to Actavis, the Company recognizes product sales at an agreed transfer price and records the related cost of products sold. Based on the terms of the Company’s distribution agreement with Actavis, the Company is entitled to a share of the ultimate profits based on the eventual net revenue from enoxaparin sales by Actavis to the end user less the agreed transfer price originally paid by Actavis to the Company. Actavis provides the Company with a quarterly sales report that calculates the Company’s share of Actavis enoxaparin gross profit. The Company records its share of Actavis gross profit as a component of net revenue. Supply Agreement with MannKind Corporation On July 31, 2014, the Company entered into a supply agreement with MannKind Corporation, or MannKind, or the Supply Agreement, pursuant to which the Company agreed to manufacture for and supply to MannKind certain quantities of RHI for use in MannKind’s product, Afrezza ® . Under the Supply Agreement, MannKind agreed to purchase annual minimum quantities of RHI in an aggregate amount of approximately €120.1 million, or approximately $146.0 million, over five years from calendar years 2015 through 2019. Specifically, the minimum annual purchase commitment was approximately €27.1 million in 2015, and approximately €23.3 million each year from 2016 through 2019. On July 31, 2014, upon entering into the Supply Agreement, MannKind paid a non-refundable prepayment to the Company in the amount of €11.0 million, or approximately $14.0 million. Under the Supply Agreement, the non-refundable prepayment was applied towards the 2015 annual commitment. The Company recorded the amount as deferred revenue in 2014, and it was recognized as net revenue in 2015 at the time the products were shipped. Unless earlier terminated, the term of the Supply Agreement expires on December 31, 2019, and can be renewed for additional, successive two-year terms upon 12 month’s written notice given prior to the end of the initial term or any additional two-year term. MannKind and the Company each have customary termination rights, including termination for material breach that is not cured within a specific time frame or in the event of liquidation, bankruptcy, or insolvency of the other party. In addition, MannKind may terminate the Supply Agreement upon two years’ prior written notice to the Company without cause or upon 30 days’ prior written notice to the Company if a controlling regulatory authority withdraws approval for Afrezza ® ; provided, however, in the event of a termination pursuant to either of these scenarios, the provisions of the supply agreement require MannKind to pay the full amount of all unpaid purchase commitments due over the initial term within 60 calendar days of the effective date of such termination. In January 2015, the Company entered into a supply option agreement with MannKind, or the Option Agreement, pursuant to which MannKind has the option to purchase RHI in excess of the minimum amounts specified in the Supply Agreement in calendar years 2016 through 2019. In the event MannKind elects not to exercise its minimum annual purchase option for any year under the Option Agreement, MannKind is obligated to pay the Company a specified capacity cancellation fee. In 2015, the sales of RHI to MannKind were €17.1 million, or approximately $20.8 million, and the unfulfilled 2015 commitment under the Supply Agreement was €6.0 million as of December 31, 2015. The Company and MannKind mutually, verbally agreed that MannKind could delay a portion of the minimum contractually obligated quantities of RHI for 2015 and purchase the remaining unfulfilled 2015 commitment in 2016. No other aspects of the Supply Agreement were modified and the commitments for calendar years 2016 through 2019 as specified in the Supply Agreement remain binding and enforceable. In October 2015, MannKind informed the Company that it was not exercising the option to purchase additional quantities of RHI for 2016 under the Option Agreement and paid the Company the specified capacity cancellation fee of $0.8 million. Such capacity cancellation fee was recorded as net revenue in the Company’s consolidated statements of operations for the year ended December 31, 2015. In the nine months ended September 30, 2016, sales of RHI to MannKind totaled $6.8 million, which fulfilled the remaining unfulfilled 2015 commitment of RHI under the Supply Agreement. MannKind had no unfulfilled purchase obligations under the Supply Agreement as of September 30, 2016, although it has not yet purchased any of its 2016 minimum purchase commitment. The Company is currently in discussions with MannKind regarding the timing of fulfillment of its minimum purchase commitment of RHI under the Supply Agreement and its purchase of additional quantities under the Option Agreement. The Company anticipates that these discussions may result in reductions in the capacity cancellation fees, as well as extensions of the timing of MannKind's purchase commitments under the Supply Agreement. Collaboration Agreement with a Medical Device Manufacturer The Company has entered into a collaboration agreement with a medical device manufacturer to develop a drug delivery system to be used by the Company for one of its pipeline products. As of September 30, 2016, the Company has paid an upfront payment of $0.5 million and $0.7 million in milestone payments under this agreement, which were classified as research and development expense. The Company is obligated to pay up to an additional $1.3 million if certain milestones are met. As of September 30, 2016, no such obligation existed. Pursuant to the collaboration agreement, if the medical device manufacturer is successful in the development of this drug delivery system and the Company’s pipeline products receive appropriate regulatory approval, the Company is obligated to enter into a commercial supply agreement with such medical device manufacturer for a minimum purchase of 1.0 million units during the first 12 months. Operating Lease Agreements The Company leases real and personal property, in the ordinary course of business, under various non-cancelable operating leases. The Company, at its option, can renew a substantial portion of its leases, at the market rate, for various renewal periods ranging from one to six years. Rental expense under these leases for the three and nine months ended September 30, 2016, was approximately $0.8 million and $2.5 million, respectively, compared to $0.8 million and $2.5 million for the three and nine months ended September 30, 2015, respectively. Purchase Commitments As of September 30, 2016, the Company has entered into commitments to purchase equipment and raw materials for an aggregate of $17.9 million. The Company anticipates that most of these commitments will be fulfilled by 2017. The Company entered into agreements with a Chinese governmental entity to acquire land-use rights to real property in Nanjing, China. Under the terms of these agreements, the Company committed to invest capital in its wholly-owned subsidiary, ANP, and to develop these properties as an API manufacturing facility for the Company’s pipeline products. In conjunction with these agreements, ANP modified its business license on July 3, 2012 to increase its authorized capital. As of September 30, 2016, the Company had invested approximately $49.0 million in ANP out of its registered capital commitment of $61.0 million. The Company has committed to invest the remaining $12.0 million in ANP by December 2017. This investment in ANP will result in cash transfers from the U.S. parent company to ANP. Per these agreements, in January 2010, the Company acquired certain land-use rights with a carrying value of $1.2 million. In addition, the Company purchased additional land-use rights in November 2012 for $1.3 million. The Company committed to spend approximately $15.0 million in land development. The agreements require the construction of fixed assets on the property and specified a timetable for the construction of these fixed assets. The current pace of development of the property is behind the schedules described in the purchase agreements and, per the purchase agreement, potential monetary penalties could result if the development is delayed or not completed in accordance with the guidelines stated in the purchase agreements. The Company is in discussions with the Chinese government regarding the development and believes that the likelihood of incurring any penalty is remote.

Litigation

Litigation	9 Months Ended
	Sep. 30, 2016
Litigation
Litigation	17. Litigation Enoxaparin Patent Litigation In September 2011, Momenta Pharmaceuticals, Inc., or Momenta, a Boston‑based pharmaceutical company, and Sandoz Inc., or Sandoz, the generic division of Novartis, initiated litigation against the Company for alleged patent infringement of two patents related to testing methods for batch release of enoxaparin, which the Company refers to as the “‘886 patent” and the “‘466 patent.” The lawsuit was filed in the United States District Court for the District of Massachusetts, or the Massachusetts District Court. In October 2011, the Massachusetts District Court issued a preliminary injunction barring the Company from selling its generic enoxaparin product and also requiring Momenta and Sandoz to post a $100.1 million bond. The preliminary injunction was stayed by the United States Court of Appeals for the Federal Circuit, or the Federal Circuit, in January 2012, and reversed by the Federal Circuit in August 2012. In January 2013, the Company moved for summary judgment of non‑infringement of both patents. Momenta and Sandoz withdrew their allegations as to the ‘466 patent, and in July 2013, the Massachusetts District Court granted the Company’s motion for summary judgment of non‑infringement of the ‘886 patent and denied Momenta and Sandoz’s motion for leave to amend their infringement contentions. On January 24, 2014, the Massachusetts District Court judge entered final judgment in the Company’s favor on both patents. Momenta and Sandoz also filed a motion to collect attorneys’ fees and costs relating to a discovery motion which the Massachusetts District Court granted. On May 9, 2016, the Massachusetts District Court issued an order imposing fees and costs of approximately $0.4 million in relation to this discovery motion. This amount has been accrued in the general and administrative expense for the quarter ended March 31, 2016 . On January 30, 2014, Momenta and Sandoz filed a notice of appeal to the Federal Circuit appealing the court’s final judgment including summary judgment denying Momenta and Sandoz’s motion for leave to amend their infringement contentions. Following appeal briefing filed by the parties, t he Federal Circuit held oral argument on May 4, 2015. On November 10, 2015, the Federal Circuit panel affirmed-in-part and vacated-in-part the decision of the Massachusetts District Court granting summary judgment of non-infringement as to the Company, and it remanded the case to the Massachusetts District Court for further proceedings consistent with its opinion. The Federal Circuit panel affirmed the Massachusetts District Court’s holding in the Company’s favor that the Company does not infringe under 35 U.S.C. 271(g), and the panel vacated the grant of summary judgment to the extent it was based on the determination that the Company’s activities fall within the 35 U.S.C. 271(e)(1) safe harbor. The Federal Circuit panel also left to the Massachusetts District Court’s discretion whether to reconsider on remand its denial of leave for Momenta and Sandoz to amend their infringement contentions. On January 11, 2016, the Company filed a Petition for Rehearing En Banc with the Federal Circuit. On February 17, 2016, the Federal Circuit denied the Company’s Petition, and the Federal Circuit issued its mandate on February 24, 2016, whereby the case returned to the Massachusetts District Court for further proceedings. On March 18, 2016, the parties filed a joint status report with the Massachusetts District Court. On June 21, 2016, the Massachusetts District Court granted Momenta and Sandoz’s Motion for Leave to Amend its Infringement Contentions. In light of Momenta and Sandoz’s Amended Infringement Contentions and recent changes in Supreme Court precedent since the case was stayed in 2012, the Company sought to amend its Non-Infringement and Invalidity Contentions. The Massachusetts District Court then held a status conference on July 6, 2016 and referred the issue of the Company’s amended contentions to the Magistrate Judge for briefing and further informed the parties that replies to any Summary Judgment motion are due in May 2017 and that trial is set to begin on July 10, 2017. On July 15, 2016, the Massachusetts District Court entered the Amended Scheduling Order setting the end of any remaining fact discovery for November 22, 2016 and the end of expert discovery for March 24, 2017. On July 18, 2016, the Company submitted its Motion for Leave to Amend Its Non-Infringement and Invalidity Contentions and Momenta and Sandoz responded on July 25, 2016. In light of the new arguments made in their response, the Company further filed a Motion For Leave to Reply in Further Support of Defendants’ Motion for Leave to Amend Non-Infringement and Invalidity Contentions. The Massachusetts District Court has not yet ruled on the Company’s pending motions regarding its amended contentions. In parallel with the Massachusetts District Court proceedings, the Company appealed the Federal Circuit’s decision to vacate the grant of the Company’s summary judgment to the extent it was based on the determination that the Company’s activities are protected under the Safe Harbor. The Company filed a Petition for a Writ of Certiorari with the Supreme Court on May 17, 2016. Momenta and Sandoz initially waived their right to respond to the petition; however, on May 31, 2016, the Supreme Court requested a response from Momenta and Sandoz. The response from Momenta and Sandoz was initially due on June 30, 2016, but they requested an extension. Momenta and Sandoz filed their response on August 1, 2016. On October 3, 2016, the Supreme Court declined the Petition for a Writ of Certiorari. The Company will continue to vigorously defend this case in the Massachusetts District Court. The Company intends to attempt to collect the $100.1 million bond posted by Momenta and Sandoz following a decision on the merits, provided that the Company prevails in Massachusetts District Court. False Claims Act Litigation In January 2009, the Company filed a qui tam complaint in the U.S. District Court for the Central District of California, or the California District Court, alleging that Aventis Pharma S.A., or Aventis, through its acquisition of a patent through false and misleading statements to the U.S. Patent and Trademark Office, as well as through false and misleading statements to the FDA, overcharged the federal and state governments for its Lovenox ® product. If the Company is successful in this litigation, it could be entitled to a portion of any damage award that the government ultimately may recover from Aventis. In October 2011, the California District Court unsealed the Company’s complaint. On February 28, 2014, Aventis filed a motion for summary judgment on the issue of the adequacy of the Company’s notice letter to the government, and the California District Court denied Aventis’ motion for summary judgment in a final order it issued on May 12, 2014. On June 9, 2014, at Aventis’ request, the California District Court issued an order certifying for appeal its order denying Aventis’ motion for summary judgment. On June 9, 2014, Aventis filed with the United States Court of Appeals for the Ninth Circuit, or the Ninth Circuit, a petition for permission to appeal the California District Court’s denial of Aventis’ motion for summary judgment, and the Company filed an opposition to Aventis’ petition on June 19, 2014. On August 22, 2014, the Ninth Circuit granted Aventis’ petition. The parties have completed and filed their respective appeal briefs with the Ninth Circuit. A date for oral argument has not been set by the Ninth Circuit. The California District Court set an evidentiary hearing for July 7, 2014 on the “original source” issue, a key element under the False Claims Act. The evidentiary hearing was conducted as scheduled, from July 7, 2014 through July 10, 2014. On July 13, 2015, the California District Court issued a ruling concluding that the Company is not an original source under the False Claims Act and entered final judgment dismissing the case for lack of subject matter jurisdiction. On July 20, 2015, the Company filed with the Ninth Circuit a notice of appeal of the California District Court’s dismissal of the case, and Aventis filed a notice of cross-appeal on August 5, 2015. On November 12, 2015, Aventis filed a pleading asking that the California District Court impose various monetary penalties and fines against the Company, including disgorgement of enoxaparin revenues and attorneys’ fees expended by Aventis in this action, based on Aventis’s allegations that the Company engaged in sanctionable conduct. On November 23, 2015, the California District Court issued an order setting forth a procedure for sanctions proceedings as to the Company as well as its outside counsel. On December 24, 2015, the Company filed a pleading with the California District Court opposing the imposition of sanctions and on January 20, 2016, Aventis filed a response pleading further pressing for the imposition of sanctions. On May 4, 2016, the California District Court issued three orders requesting that the Company and its outside counsel file a document showing cause as to why sanctions should not be imposed and to set up a conference call with the partiers and the court to discuss whether any discovery and/or a hearing is necessary. On June 13, 2016, the Company and its outside counsel each filed responses to the court’s order to show cause as to why sanctions should not be imposed. On July 21, 2016, Aventis filed a response contending that the court should impose sanctions. The Company intends to continue to vigorously defend against any such imposition of sanctions. On March 28, 2016, the Company filed its opening brief with the Ninth Circuit Court of Appeals setting forth detailed arguments as to why the False Claims Act litigation should not have been dismissed by the California District Court. On June 20, 2016, Aventis filed its principal brief in the appeal, responding to the Company’s arguments regarding dismissal of the False Claims Act litigation, and setting forth Aventis’s argument that it should be awarded attorneys’ fees and expenses. On September 19, 2016, the Company filed its reply brief to Aventis’s principal brief. On October 3, 2016, Aventis filed its reply brief in support of its cross-appeal of the District Court’s denial of attorneys’ fees. The Ninth Circuit has scheduled oral arguments to be heard on November 10, 2016. California Employment Litigation On January 6, 2015, the Company received a formal demand from Plaintiff’s counsel in an employment related lawsuit captioned Eva Hernandez v. International Medication Systems Limited, in connection with a complaint originally filed on February 4, 2013 in the Superior Court of California County of Los Angeles, or the Court, by plaintiff Eva Hernandez on behalf of herself and others similarly situated. Plaintiff’s complaint included alleged violations of the California Labor Code stemming from the Company’s alleged timekeeping practices, as well as other similar and related claims brought under California law. In the complaint, Plaintiff sought damages and related remedies under California law, as well as various penalty payments under the California Labor Code, on behalf of herself and others similarly situated. On April 7, 2015, solely to resolve the dispute, minimize disruption to the Company due to ongoing litigation, and other similar and related factors (but unrelated to the alleged merits of Plaintiff’s claims), the Company reached an agreement in principle to settle this matter on a class-wide basis for a total amount of $3.2 million, plus applicable payroll taxes. The Joint Stipulation of Settlement as executed by the parties was filed with the Court on June 2, 2015. On July 1, 2015, the Court preliminarily approved the settlement, and on November 5, 2015, the Court entered an order granting final approval of the settlement. Momenta/Sandoz Antitrust Litigation On September 17, 2015, the Company initiated a lawsuit by filing a complaint in the California District Court against Momenta and Sandoz, or Defendants. The Company’s complaint generally asserts that Defendants have engaged in certain types of illegal, monopolistic, and anticompetitive conduct giving rise to various causes of action against them. On December 9, 2015, Defendants filed a motion to dismiss and a motion to transfer the case to the District of Massachusetts. On January 4, 2016, the Company filed oppositions to both motions. On January 26, 2016, the California District Court granted Defendants’ motion to transfer and did not rule on Defendants’ motion to dismiss. Accordingly, the case was transferred to the District of Massachusetts. On February 9, 2016, the Company filed a writ of mandamus with the Ninth Circuit to attempt to appeal the California District Court’s granting of Defendants’ motion to transfer to the District of Massachusetts. The Ninth Circuit denied this petition on May 20, 2016, and as such the case will remain before the District of Massachusetts. On July 27, 2016, the Massachusetts District Court granted Defendants’ motion to dismiss based upon an antitrust immunity doctrine, without addressing the substantive merits of the claims. On August 25, 2016, the Company filed with the First Circuit Court of Appeals a notice of appeal of the Massachusetts District Court’s dismissal of the antitrust case. Other Litigation The Company is also subject to various other claims and lawsuits from time-to-time arising in the ordinary course of business. The Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. In the opinion of management, the ultimate resolution of any such matters is not expected to have a material adverse effect on its financial position, results of operations, or cash flows; however, the results of litigation and claims are inherently unpredictable and the Company’s view of these matters may change in the future. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2016
Subsequent Events
Subsequent Events	18. Subsequent Events On November 7, 2016, the Company’s Board of Directors authorized an increase of $20.0 million to the Company’s share buyback program, which is expected to continue for an indefinite period of time. The primary goal of the program is to offset dilution created by the Company’s equity compensation programs. Purchases may be made through the open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions or other means as determined by the Company’s management and in accordance with the requirements of the SEC. The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions.

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2016
Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation All significant intercompany activity has been eliminated in the preparation of the condensed consolidated financial statements. The unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of Form 10-Q and Rule 10-01 of Regulation S-X. Some information and footnote disclosures normally included in financial statements prepared in accordance with GAAP, have been condensed or omitted pursuant to those rules and regulations. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the condensed consolidated financial position, results of operations, and cash flows of the Company. The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: International Medication Systems, Limited, or IMS; Armstrong Pharmaceuticals, Inc., or Armstrong; Amphastar Nanjing Pharmaceuticals Co., Ltd., or ANP; Nanjing Letop Fine Chemistry Co., Ltd., or Letop, Amphastar France Pharmaceuticals, S.A.S., or AFP, Amphastar UK Ltd., or AUK, and International Medication Systems (UK) Limited, or IMS UK.
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The principal accounting estimates include: determination of allowances for doubtful accounts and discounts, provision for chargebacks, liabilities for product returns, reserves for excess or unsellable inventory, impairment of long-lived and intangible assets and goodwill, self-insured claims, workers’ compensation liabilities, litigation reserves, stock price volatilities for share-based compensation expense, valuation allowances for deferred tax assets, and liabilities for uncertain income tax positions.
Foreign Currency	Foreign Currency The functional currency of the Company, its Chinese subsidiary, ANP, and its U.K. subsidiary, AUK, is the U.S. dollar, or USD. ANP maintains its books of record in Chinese Yuan. These books are remeasured into the functional currency of USD using the current or historical exchange rates. The resulting currency remeasurement adjustments and other transactional foreign currency exchange gains and losses are reflected in the Company’s statements of operations. The Company’s French subsidiary, AFP, Chinese subsidiary, Letop, and U.K. subsidiary, IMS UK, maintain their books of record in Euros, Chinese Yuan, and Great Britain Pounds, respectively, which are the local currencies and have been determined to be their respective functional currencies. These books are translated into USD using average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transactions. Translation adjustments are reflected in stockholders’ equity and are included as a component of other comprehensive income (loss). The gains or losses of intercompany foreign currency transactions that are of a long-term investment nature are reported in other comprehensive income (loss). The gains and losses of intercompany foreign currency transactions for the three and nine months ended September 30, 2016 were a $0.3 million gain and a $0.6 million gain, respectively, and for the three and nine months ended September 30, 2015 were a $0.3 million gain and a $1.6 million loss, respectively. Additionally, the Company does not undertake hedging transactions to cover its foreign currency exposure.
Comprehensive Income (Loss)	Comprehensive Income (Loss) For the three and nine months ended September 30, 2016 and 2015, the Company included its foreign currency translation adjustment as part of its comprehensive income (loss).
Financial Instruments	Financial Instruments The carrying amounts of cash and cash equivalents, short-term investments, restricted short-term investments, accounts receivable, accounts payable, accrued expenses, and short-term borrowings approximate fair value due to the short maturity of these items. A majority of the Company’s long-term obligations consist of variable rate debt, and their carrying value approximates fair value as the stated borrowing rates are comparable to rates currently offered to the Company for instruments with similar maturities. However, the Company has one fixed-rate, long-term mortgage for which the carrying value differs from the fair value and is not remeasured on a recurring basis (see Note 12).
Deferred Income Taxes	Deferred Income Taxes The Company utilizes the liability method of accounting for income taxes, under which deferred taxes are determined based on the temporary differences between the financial statements and the tax basis of assets and liabilities using enacted tax rates. A valuation allowance is recorded when it is more likely than not that the deferred tax assets will not be realized. The Company has adopted the with-and-without methodology for determining when excess tax benefits from the exercise of share‑based awards are realized. Under the with-and-without methodology, current year operating loss deductions and prior-year operating loss carryforwards are deemed to be utilized prior to the utilization of current-year excess tax benefits from share‑based awards.
Business Combinations	Business Combinations Business combinations are accounted for in accordance with Accounting Standards Codification, or ASC 805, Business Combinations, using the acquisition method of accounting, which requires an acquirer to recognize the assets acquired and the liabilities assumed at the acquisition date measured at their fair values as of that date. Fair value determinations are based on discounted cash flow analyses or other valuation techniques. In determining the fair value of the assets acquired and liabilities assumed in a material acquisition, the Company may utilize appraisals from third party valuation firms to determine fair values of some or all of the assets acquired and liabilities assumed, or may complete some or all of the valuations internally. In either case, the Company takes full responsibility for the determination of the fair value of the assets acquired and liabilities assumed. The value of goodwill reflects the excess of the fair value of the consideration conveyed to the seller over the fair value of the net assets received. Acquisition-related costs that the Company incurs to effect a business combination are expensed in the periods in which the costs are incurred.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board, or FASB, issued an accounting standards update that creates a single source of revenue guidance for companies in all industries. The new standard provides guidance for all revenue arising from contracts with customers and affects all entities that enter into contracts to provide goods or services to their customers, unless the contracts are within the scope of other accounting standards. It also provides a model for the measurement and recognition of gains and losses on the sale of certain nonfinancial assets. This guidance must be adopted using either a full retrospective approach for all periods presented or a modified retrospective approach and will be effective for fiscal years beginning after December 15, 2017, which will be the Company’s fiscal 2018. The Company has not yet evaluated the potential impact of adopting the guidance on the Company’s condensed consolidated financial statements. In August 2014, the FASB issued an accounting standards update that will require management to evaluate if there is substantial doubt about the Company’s ability to continue as a going concern and, if so, to disclose this in both interim and annual reporting periods. This guidance will become effective for the Company’s annual filing for the period ending December 31, 2016, and interim reporting periods thereafter, and allows for early adoption. The Company does not expect the adoption of the guidance will have a material impact on the Company’s condensed consolidated financial statements. In July 2015, the FASB issued an accounting standards update which requires entities to measure most inventories at the lower of cost or net realizable value, or NRV, thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market. Under the new guidance, inventory is measured at the lower of cost or net realizable value, which eliminates the need to determine replacement cost and evaluate whether it is above the ceiling (NRV) or below the floor (NRV less a normal profit margin). The guidance defines NRV as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for annual periods beginning after December 15, 2016, and interim reporting periods therein. The standard will be effective for the Company for the first quarter of the Company’s fiscal 2017. Early application is permitted. The new guidance must be applied prospectively. The Company does not believe the adoption of this accounting guidance will have a material impact on the Company’s condensed consolidated financial statements and related disclosures. In November 2015, the FASB issued an accounting standards update to the balance sheet classification of deferred taxes. Under existing standards, deferred taxes for each tax-paying jurisdiction are presented as a net current asset or liability and net long-term asset or liability. To simplify presentation, the new guidance will require that all deferred tax assets and liabilities, along with related valuation allowances, be classified as long-term on the balance sheet. As a result, each tax-paying jurisdiction will now only have one net long-term deferred tax asset or liability. The new guidance does not change the existing requirement that prohibits offsetting deferred tax liabilities from one jurisdiction against deferred tax assets of another jurisdiction. The guidance is effective for annual periods beginning after December 15, 2016, and interim reporting periods therein. Early adoption is permitted. The new guidance may be applied prospectively or retrospectively. The Company has elected to adopt the guidance early and apply the guidance prospectively. Therefore, prior periods were not retrospectively adjusted. The reclassification of the Company’s deferred tax assets and liabilities does not have any impact on the Company’s net income or cash flow; thus, the adoption of the guidance does not have a material impact on the Company’s condensed consolidated financial statements. In February 2016, the FASB issued an accounting standards update that is aimed at making leasing activities more transparent and comparable, and which requires substantially all leases to be recognized by lessees on their balance sheets as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. This guidance will become effective for the Company’s interim and annual reporting periods during the year ending December 31, 2019, and all annual and interim reporting periods thereafter. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its condensed consolidated financial statements and related disclosures. In March 2016, the FASB issued an accounting standards update that is aimed at improving the employee share-based payment accounting. The standard update simplifies the accounting for employee share-based payments and involves several aspects of the accounting for share-based transactions, including the potential timing of expenses, the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The guidance is effective for annual periods beginning after December 15, 2016, and interim reporting periods therein. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its condensed consolidated financial statements and related disclosures. In June 2016, the FASB issued an accounting standards update that is aimed at providing financial statement users with more useful information about the expected credit losses on financial instruments and other commitments to extend credit. The standard update changes the impairment model for financial assets measured at amortized cost, requiring presentation at the net amount expected to be collected. The measurement of expected credit losses requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Available-for-sale debt securities with unrealized losses will be recorded through an allowance for credit losses. The guidance is effective for the Company’s interim and annual reporting periods during the year ending December 31, 2020. The Company is currently evaluating the impact that the adoption of this guidance will have on its condensed consolidated financial statements and related disclosures. In August 2016, the FASB issued an accounting standards update that is aimed at addressing certain issues regarding classifications of certain cash receipt and cash payment on the statement of cash flows where diversity in practice was identified. The guidance is effective for the Company’s interim and annual reporting periods during the year ending December 31, 2018. Early adoption is permitted. The Company does not believe that the adoption of this accounting guidance will have a material impact on the Company’s condensed consolidated financial statements and related disclosures.
Revenue Recognition	Generally, revenue is recognized at the time of product delivery to the Company’s customers. In some cases, revenue is recognized at the time of shipment when stipulated by the terms of the sale agreements. The Company also records profit-sharing revenue stemming from a distribution agreement with Actavis, Inc., or Actavis. This distribution agreement is in the process of being terminated (see Note 16). Profit-sharing revenue is recognized at the time Actavis sells the products to its customers. Revenues derived from contract manufacturing services are recognized when third-party products are shipped to customers, after the customer has accepted test samples of the products to be shipped. The Company does not recognize product revenue unless the following fundamental criteria are met: (i) persuasive evidence that an arrangement exists, (ii) transfer of title has occurred, (iii) the price to the customer is fixed or determinable, and (iv) collection is reasonably assured. Furthermore, the Company does not recognize revenue until all customer acceptance requirements have been met. The Company estimates and records reductions to revenue for discounts, product returns, and pricing adjustments, such as wholesaler chargebacks, in the same period that the related revenue is recorded. The Company’s accounting policy is to review each agreement involving contract development and manufacturing services to determine if there are multiple revenue-generating activities that constitute more than one unit of accounting. Revenues are recognized for each unit of accounting based on revenue recognition criteria relevant to that unit. The Company does not have any revenue arrangements with multiple deliverables.

Business Acquisitions (Tables)

Business Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2016
Business Acquisitions
Schedule of payments for business acquisition	U.S. Euros Dollars (in thousands) At Closing, April 2014 € $ December 2014 December 2015 December 2016 December 2017 € $

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2016
Revenue Recognition
Schedule of chargeback provision analysis	Nine Months Ended September 30, 2016 2015 (in thousands) Beginning balance $ $ Provision related to sales made in the current period Credits issued to third parties Ending balance $ $
Schedule of product return liability analysis	Nine Months Ended September 30, 2016 2015 (in thousands) Beginning balance $ $ Provision for product returns Credits issued to third parties Ending balance $ $

Income (Loss) per Share (Tables

Income (Loss) per Share (Tables)	9 Months Ended
	Sep. 30, 2016
Income (Loss) per Share
Schedule of basic and diluted net income (loss) per share calculation	Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 (in thousands, except per share data) Basic and dilutive numerator: Net income (loss) $ $ $ $ Denominator: Weighted-average shares outstanding — basic Net effect of dilutive securities: Incremental shares from equity awards — — Weighted-average shares outstanding — diluted Net income (loss) per share — basic $ $ $ $ Net income (loss) per share — diluted $ $ $ $

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2016
Segment Reporting
Schedule of financial information by reporting segment	Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 (in thousands) Net revenues: Finished pharmaceutical products $ $ $ $ API Total net revenues Gross profit: Finished pharmaceutical products API Total gross profit Operating expenses Income (loss) from operations Non-operating income (expenses) Income (loss) before income taxes $ $ $ $
Schedule of net revenues in the finished pharmaceutical products segment	Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 (in thousands) Finished pharmaceutical products net revenues: Enoxaparin $ $ $ $ Naloxone Lidocaine Phytonadione Epinephrine Other finished pharmaceutical products Total finished pharmaceutical products net revenues $ $ $ $
Schedule of net revenues and long-lived assets by geographic region	Net Revenue Long-Lived Assets Three Months Ended Nine Months Ended September 30, September 30, September 30, December 31, 2016 2015 2016 2015 2016 2015 (in thousands) United States $ $ $ $ $ $ China — — — — France United Kingdom — — — — — Total $ $ $ $ $ $

Customer and Supplier Concent30

Customer and Supplier Concentration (Tables)	9 Months Ended
	Sep. 30, 2016
Customer and Supplier Concentration
Schedule of accounts receivable and net revenues by major customer	% of Total Accounts % of Net Receivable Revenue Three Months Ended Nine Months Ended September 30, December 31, September 30, September 30, 2016 2015 2016 2015 2016 2015 Actavis (1) % % % % % % AmerisourceBergen % % % % % % Cardinal Health % % % % % % MannKind Corporation % % % % % % McKesson % % % % % % (1) Effective June 30, 2016, the Company and Actavis agreed to terminate the agreement upon the earlier of (i) January 1, 2017, and (ii) such earlier date that is 30 days after Actavis notifies the Company in writing that Actavis has less than 30 days inventory of the enoxaparin product remaining in its possession or scheduled to be delivered pursuant to the pending purchase orders (see Note 16).

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2016
Fair Value Measurements
Schedule of financial assets and liabilities measured on a recurring basis	Quoted Prices in Active Markets Significant Other Significant Other for Identical Observable Unobservable Assets Inputs Inputs Total (Level 1) (Level 2) (Level 3) (in thousands) Cash equivalents $ $ $ — $ — Restricted short-term investments — — Fair value measurement as of September 30, 2016 $ $ $ — $ — Cash equivalents $ $ $ — $ — Restricted short-term investments — — Fair value measurement as of December 31, 2015 $ $ $ — $ —

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets
Schedule of weighted-average life, original cost, accumulated amortization and net book value by major class	Weighted-Average Accumulated Life (Years) Original Cost Amortization Net Book Value (in thousands) Definite-lived intangible assets Product rights 12 $ $ $ Acquired international product rights (1) 10 Acquired ANDAs (2) 15 Patents 10 Land-use rights 39 Other intangible assets 1 Subtotal 12 Indefinite-lived intangible assets Trademark * — Goodwill Finished pharmaceutical products * — Subtotal * — As of September 30, 2016 * $ $ $ * (1) In August 2016, the Company acquired International Medication Systems (UK) Limited from UCB PHARMA GmbH for $7.7 million. The fair value of the marketing authorization was $9.2 million as of the acquisition date. The accounting for this transaction is preliminary (see Note 3). (2) In March 2016, the Company acquired 14 ANDAs representing 11 different injectable chemical entities from Hikma Pharmaceuticals PLC for $4.0 million. The accounting for this transaction is preliminary (see Note 3). Weighted-Average Accumulated Life (Years) Original Cost Amortization Net Book Value (in thousands) Definite-lived intangible assets Product rights 12 $ $ $ Patents 10 Land-use rights 39 Other intangible assets 1 Subtotal 12 Indefinite-lived intangible assets Trademark * — Goodwill Finished pharmaceutical products * — Subtotal * — As of December 31, 2015 * $ $ $ * Intangible assets with indefinite lives have an indeterminable average life.
Schedule of changes in carrying amounts of goodwill	September 30, December 31, 2016 2015 (in thousands) Beginning balance $ $ Goodwill related to acquisition of business — Currency translation and other adjustments Ending balance $ $

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2016
Inventories
Schedule of inventories	September 30, December 31, 2016 2015 (in thousands) Raw materials and supplies $ $ Work in process Finished goods Total inventory Less reserve for excess and obsolete inventories Total inventory, net $ $

Property, Plant, and Equipment

Property, Plant, and Equipment (Tables)	9 Months Ended
	Sep. 30, 2016
Property, Plant, and Equipment
Schedule of property, plant, and equipment	September 30, December 31, 2016 2015 (in thousands) Buildings $ $ Leasehold improvements Land Machinery and equipment Furniture, fixtures, and automobiles Construction in progress Total property, plant, and equipment Less accumulated depreciation Total property, plant, and equipment, net $ $

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2016
Debt
Schedule of debt	September 30, December 31, 2016 2015 (in thousands) Loans with East West Bank Mortgage payable matured January 2016 $ — $ Mortgage payable matured September 2016 — Equipment loan due April 2017 Line of credit facility due September 2017 — — Equipment loan due January 2019 Mortgage payable due February 2021 — Equipment credit line due September 2021 — Mortgage payable due October 2026 — Loans with Cathay Bank Line of credit facility due May 2018 — — Acquisition loan due April 2019 Mortgage payable due April 2021 Loans with Seine-Normandie Water Agency French government loan 1 due March 2018 French government loan 2 due June 2020 French government loan 3 due July 2021 Payment Obligation to Merck Equipment under Capital Leases Total debt and capital leases Less current portion of long-term debt and capital leases Long-term debt and capital leases, net of current portion $ $

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2016
Income Taxes
Schedule of reconciliation of the statutory federal income tax rate	Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 (in thousands) Income (loss) before taxes $ $ $ $ Income tax expense (benefit) Net income (loss) $ $ $ $ Income tax provision (benefit) as a percentage of income (loss) before income taxes % % % %

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2016
Stockholders' Equity
Schedule of key assumptions to determine fair value of options	Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Average volatility % % % % Risk-free interest rate % % % % Weighted-average expected life in years Dividend yield rate — % — % — % — %
Schedule of the summary of option activity under all plans	Weighted-Average Weighted-Average Remaining Aggregate Exercise Contractual Intrinsic Options Price Term (Years) Value (1) (in thousands) Outstanding as of December 31, 2015 $ Options granted Options exercised Options cancelled Options expired Outstanding as of September 30, 2016 $ $ Exercisable as of September 30, 2016 $ $ The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the estimated fair value of the Company’s common stock for those awards that have an exercise price below the estimated fair value at September 30, 2016.
Schedule of information relating to options grants	Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 (in thousands, except per share data) Weighted-average grant date fair value $ $ $ $ Intrinsic value of options exercised Cash received Total fair value of the options vested during the year
Schedule of the summary of nonvested options status	Weighted-Average Grant Date Options Fair Value Nonvested as of December 31, 2015 $ Options granted Options vested Options forfeited Nonvested as of September 30, 2016
Schedule of information relating to RSU grants and deliveries	Total Fair Market Value of RSUs Issued Total RSUs as Issued Compensation (1) (in thousands) RSUs outstanding at December 31, 2015 RSUs granted $ RSUs forfeited Common stock delivered RSUs surrendered for taxes RSUs outstanding at September 30, 2016 The total fair market value is derived from the number of RSUs granted times the current stock price on the date of grant.
Schedule of recorded share-based compensation expense under all plans	Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 (in thousands) Cost of revenues $ $ $ $ Operating expenses: Selling, distribution, and marketing General and administrative Research and development Total share-based compensation $ $ $ $
Schedule of changes in stockholders' equity	Nine Months Ended September 30, 2016 (in thousands) Stockholders’ equity as of December 31, 2015 $ Net income Accumulated other comprehensive loss Exercise of stock options Issuance of common stock to employees under the ESPP Nonemployee share-based compensation expense Employee share-based compensation expense Repurchase of common stock (1) Purchase of treasury stock Stockholders’ equity as of September 30, 2016 $ (1) Repurchase of common stock relating to the tax withholding of equity award settlements.

Summary of Significant Accoun38

Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Summary of Significant Accounting Policies
Gains and losses of intercompany foreign currency transactions	$ 0.3	$ 0.3	$ 0.6	$ (1.6)

Business Acquisitions (Narrativ

Business Acquisitions (Narrative) (Details) $ in Thousands, € in Millions	Apr. 30, 2014USD ($)	Apr. 30, 2014EUR (€)	Aug. 31, 2016USD ($)item	Mar. 31, 2016USD ($)item	Jan. 31, 2016USD ($)	Sep. 30, 2016USD ($)	Dec. 31, 2015
Business Acquisition
Payment to Acquire Business, Gross						$ 12,461
Useful life of acquired intangibles						12 years	12 years
Goodwill related to acquisition of business						$ 391
International Medication Systems (UK) Limited
Business Acquisition
Number of Marketing Authorizations Acquired | item			33
Number of Different Injectable Chemical Entities | item			11
Payment to Acquire Business, Gross			$ 7,700
Marketing authorizations acquired			9,200
Manufacturing equipment acquired			100
Deferred tax liability assumed			$ 1,600
Useful life of acquired intangibles			10 years
Hikma Pharmaceuticals PLC
Business Acquisition
Number of Different Injectable Chemical Entities | item				11
Payment to Acquire Business, Gross				$ 4,000
Useful life of acquired intangibles				15 years
Number of Injectable Products Acquired | item				14
Assets acquired				$ 4,000
Merck Sharpe & Dohme's API
Business Acquisition
Purchase price	$ 34,400	€ 24.8
Letop
Business Acquisition
Purchase price					$ 1,700
Payment to Acquire Business, Gross					800
Deposit that ANP previously paid which was effectively eliminated upon the consummation of the transaction					900
Assets acquired					1,400
Liabilities assumed					$ 100

Business Acquisitions (Acquisit

Business Acquisitions (Acquisition of Merck’s API Manufacturing Business) (Details) - Merck Sharpe & Dohme's API € in Thousands, $ in Thousands	Apr. 30, 2014USD ($)	Apr. 30, 2014EUR (€)	Apr. 30, 2014USD ($)	Apr. 30, 2014EUR (€)
Business Acquisition
Purchase price	$ 34,400	€ 24,800
At Closing, April 2014			$ 18,352	€ 13,252
December 2,014			5,989	4,899
December 2,015			3,483	3,186
December 2,016			3,572	3,186
December 2,017			561	500
Total - estimated			$ 31,957	€ 25,023

Revenue Recognition (Analysis o

Revenue Recognition (Analysis of the Chargeback Provision) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Revenue Recognition
Beginning balance	$ 15,217	$ 11,872
Provision related to sales made in the current period	105,772	121,714
Credits issued to third parties	(110,073)	(121,914)
Ending balance	$ 10,916	$ 11,672

Revenue Recognition (Analysis42

Revenue Recognition (Analysis of Product Return Liability) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Revenue Recognition
Beginning balance	$ 2,621	$ 2,408
Provision for product returns	958	1,971
Credits issued to third parties	(873)	(1,233)
Ending balance	$ 2,706	$ 3,146
Aggregate product return rate	1.10%	1.10%

Income (Loss) per Share (Narrat

Income (Loss) per Share (Narrative) (Details) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,357,154	12,471,789	4,510,729	12,471,789
Antidilutive Securities Excluded from Computation of Earnings Per Share, Exercise Price of Excluded Securities	$ 29.31		$ 19.84
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		877,665		877,665
Employee Stock Purchase Plan (ESPP)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		165,167		165,167

Income (Loss) per Share (Calcul

Income (Loss) per Share (Calculation of Basic and Diluted Net Loss Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Basic and dilutive numerator:
Net income (loss)	$ 3,890	$ (3,008)	$ 13,274	$ (10,320)
Denominator:
Shares outstanding	45,398	45,310	45,132	44,920
Weighted-average shares outstanding—basic	45,398	45,310	45,132	44,920
Net effect of dilutive securities:
Incremental shares from equity awards	2,555		1,233
Weighted-average shares outstanding — diluted	47,953	45,310	46,365	44,920
Net income (loss) per share — basic	$ 0.09	$ (0.07)	$ 0.29	$ (0.23)
Net income (loss) per share — diluted	$ 0.08	$ (0.07)	$ 0.29	$ (0.23)

Segment Reporting (Selected Fin

Segment Reporting (Selected Financial Information by Reporting Segment) (Details) $ in Thousands, € in Millions	3 Months Ended		9 Months Ended			30 Months Ended
	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)segment	Sep. 30, 2016EUR (€)segment	Sep. 30, 2015USD ($)	Sep. 30, 2016EUR (€)
Segment Reporting Information [Line Items]
Number of Reportable Segments | segment			2	2
Net revenues:
Net Revenue	$ 64,223	$ 63,868	$ 191,622		$ 174,607
Gross Profit:
Gross Profit	27,612	17,578	84,228		44,176
Operating expenses	21,815	21,326	64,026		65,445
Income (loss) from operations	5,797	(3,748)	20,202		(21,269)
Non-operating income (expenses)	204	(528)	(633)		567
Income (loss) before income taxes	6,001	(4,276)	19,569		(20,702)
Finished Pharmaceutical Products
Net revenues:
Net Revenue	59,058	57,902	181,368		158,849
Gross Profit:
Gross Profit	28,621	19,302	85,042		44,789
API
Segment Reporting Information [Line Items]
Remediation expense incurred in connection with API acquisition | €				€ 0.6		€ 0.6
Environmental remediation threshold provided by Merck for expenses incurred | €				€ 6
Net revenues:
Net Revenue	5,165	5,966	10,254		15,758
Gross Profit:
Gross Profit	$ (1,009)	$ (1,724)	$ (814)		$ (613)

Segment Reporting (Summary of N

Segment Reporting (Summary of Net Revenues by Product Segment) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	$ 64,223	$ 63,868	$ 191,622	$ 174,607
Finished Pharmaceutical Products
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	59,058	57,902	181,368	158,849
Finished Pharmaceutical Products | Enoxaparin
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	15,363	21,264	51,049	64,647
Finished Pharmaceutical Products | Naloxone
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	12,407	10,519	38,222	27,944
Finished Pharmaceutical Products | Phytonadione
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	8,667	5,935	23,555	10,301
Finished Pharmaceutical Products | Epinephrine
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	5,303	5,032	14,921	9,958
Finished Pharmaceutical Products | Lidocaine
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	8,279	6,176	26,378	20,662
Finished Pharmaceutical Products | Other Finished Pharmaceutical Products
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	$ 9,039	$ 8,976	$ 27,243	$ 25,337

Segment Reporting (Summary of R

Segment Reporting (Summary of Revenues and Long-Lived Assets by Geographic Region) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Revenue	$ 64,223	$ 63,868	$ 191,622	$ 174,607
Long-Lived Assets	151,952		151,952		$ 142,161
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Revenue	62,691	62,955	188,865	168,705
Long-Lived Assets	103,179		103,179		100,404
CHINA
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	34,541		34,541		28,547
FRANCE
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Revenue	1,532	$ 913	2,757	$ 5,902
Long-Lived Assets	14,135		14,135		$ 13,210
UNITED KINGDOM
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	$ 97		$ 97

Customer and Supplier Concent48

Customer and Supplier Concentration (Details) - Customer Concentration Risk [Member] - item	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Revenue, Major Customer [Line Items]
Number of major customers that are wholesale distributors			3
Accounts Receivable
Revenue, Major Customer [Line Items]
Number of major customers			5		5
Net Revenues
Revenue, Major Customer [Line Items]
Number of major customers	5	5	5	5	5
Actavis, Inc. | Accounts Receivable
Revenue, Major Customer [Line Items]
Major Customers			10.00%		12.00%
Actavis, Inc. | Net Revenues
Revenue, Major Customer [Line Items]
Major Customers	16.00%	22.00%	19.00%	22.00%
AmerisourceBergen | Accounts Receivable
Revenue, Major Customer [Line Items]
Major Customers			13.00%		12.00%
AmerisourceBergen | Net Revenues
Revenue, Major Customer [Line Items]
Major Customers	19.00%	17.00%	19.00%	17.00%
Cardinal Health | Accounts Receivable
Revenue, Major Customer [Line Items]
Major Customers			23.00%		20.00%
Cardinal Health | Net Revenues
Revenue, Major Customer [Line Items]
Major Customers	19.00%	14.00%	20.00%	16.00%
MannKind Corporation | Accounts Receivable
Revenue, Major Customer [Line Items]
Major Customers			12.00%		13.00%
MannKind Corporation | Net Revenues
Revenue, Major Customer [Line Items]
Major Customers	5.00%	7.00%	4.00%	7.00%
McKesson | Accounts Receivable
Revenue, Major Customer [Line Items]
Major Customers			20.00%		21.00%
McKesson | Net Revenues
Revenue, Major Customer [Line Items]
Major Customers	21.00%	25.00%	20.00%	22.00%

Fair Value Measurements (Fair V

Fair Value Measurements (Fair Values of the Company’s Financial Assets and Liabilities) (Details) - Recurring Basis - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Restricted short-term investments:
Fair value measurement	$ 46,085	$ 43,771
Money market accounts
Cash equivalents:
Cash equivalents	44,695	42,486
Certificates of deposit
Restricted short-term investments:
Restricted short-term investments	1,390	1,285
Level 1
Restricted short-term investments:
Fair value measurement	46,085	43,771
Level 1 | Money market accounts
Cash equivalents:
Cash equivalents	44,695	42,486
Level 1 | Certificates of deposit
Restricted short-term investments:
Restricted short-term investments	$ 1,390	$ 1,285

Goodwill and Intangible Asset50

Goodwill and Intangible Assets (Summary of Intangible Assets) (Details) $ in Thousands	1 Months Ended		9 Months Ended	12 Months Ended
	Aug. 31, 2016USD ($)item	Mar. 31, 2016USD ($)item	Sep. 30, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Definite-lived intangible assets
Weighted-Average Life (Years)			12 years	12 years
Finite-Lived Intangible Assets, Gross			$ 43,616	$ 30,557
Accumulated Amortization			25,319	23,607
Finite-Lived Intangible Assets, Net			18,297	6,950
Indefinite-lived intangible assets
Goodwill recognized			4,210	3,726	$ 4,467
Subtotal, Original Cost			33,435	32,951
Subtotal, Net Book Value			33,435	32,951
Balance, Original Cost			77,051	63,508
Balance, Net Book Value			51,732	39,901
Payment to Acquire Business, Gross			12,461
Finished Pharmaceutical Products
Indefinite-lived intangible assets
Goodwill recognized			4,210	3,726
Trademarks
Indefinite-lived intangible assets
Indefinite-lived intangible assets			$ 29,225	$ 29,225
Product rights
Definite-lived intangible assets
Weighted-Average Life (Years)			12 years	12 years
Finite-Lived Intangible Assets, Gross			$ 27,134	$ 27,134
Accumulated Amortization			24,015	22,679
Finite-Lived Intangible Assets, Net			$ 3,119	$ 4,455
Acquired international product rights
Definite-lived intangible assets
Weighted-Average Life (Years)			10 years
Finite-Lived Intangible Assets, Gross			$ 9,075
Accumulated Amortization			151
Finite-Lived Intangible Assets, Net			$ 8,924
Acquired ANDAs
Definite-lived intangible assets
Weighted-Average Life (Years)			15 years
Finite-Lived Intangible Assets, Gross			$ 4,000
Accumulated Amortization			156
Finite-Lived Intangible Assets, Net			$ 3,844
Patents
Definite-lived intangible assets
Weighted-Average Life (Years)			10 years	10 years
Finite-Lived Intangible Assets, Gross			$ 293	$ 293
Accumulated Amortization			129	107
Finite-Lived Intangible Assets, Net			$ 164	$ 186
Land-use rights
Definite-lived intangible assets
Weighted-Average Life (Years)			39 years	39 years
Finite-Lived Intangible Assets, Gross			$ 2,540	$ 2,540
Accumulated Amortization			337	288
Finite-Lived Intangible Assets, Net			$ 2,203	$ 2,252
Other intangible assets
Definite-lived intangible assets
Weighted-Average Life (Years)			1 year	1 year
Finite-Lived Intangible Assets, Gross			$ 574	$ 590
Accumulated Amortization			531	533
Finite-Lived Intangible Assets, Net			$ 43	$ 57
International Medication Systems (UK) Limited
Definite-lived intangible assets
Weighted-Average Life (Years)	10 years
Indefinite-lived intangible assets
Marketing authorizations acquired	$ 9,200
Payment to Acquire Business, Gross	$ 7,700
Number of Different Injectable Chemical Entities | item	11
Hikma Pharmaceuticals PLC
Definite-lived intangible assets
Weighted-Average Life (Years)		15 years
Indefinite-lived intangible assets
Payment to Acquire Business, Gross		$ 4,000
Number of Injectable Products Acquired | item		14
Number of Different Injectable Chemical Entities | item		11

Goodwill and Intangible Asset51

Goodwill and Intangible Assets (Summary of Changes in the Carrying Amount of Goodwill) (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Goodwill and Intangible Assets
Beginning balance	$ 3,726	$ 4,467
Goodwill related to acquisition of business	391
Currency translation and other adjustments	93	(741)
Ending balance	$ 4,210	$ 3,726

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Inventories
Raw materials and supplies	$ 47,240	$ 31,878
Work in process	15,645	21,455
Finished goods	29,351	19,867
Total inventory	92,236	73,200
Less reserve for excess and obsolete inventories	(1,586)	(2,535)
Total inventory, net	$ 90,650	$ 70,665

Property, Plant, and Equipmen53

Property, Plant, and Equipment (Summary of Property, Plant, and Equipment) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Capitalized manufacturing equipment for specific use	$ 271,401	$ 254,419
Less accumulated depreciation and amortization	(119,449)	(112,258)
Total property, plant, and equipment, net	151,952	142,161
Buildings
Property, Plant and Equipment [Line Items]
Capitalized manufacturing equipment for specific use	84,533	82,309
Leasehold improvement
Property, Plant and Equipment [Line Items]
Capitalized manufacturing equipment for specific use	24,638	23,392
Land
Property, Plant and Equipment [Line Items]
Capitalized manufacturing equipment for specific use	6,926	6,895
Machinery and equipment
Property, Plant and Equipment [Line Items]
Capitalized manufacturing equipment for specific use	110,371	108,442
Furniture, fixtures, and automobiles
Property, Plant and Equipment [Line Items]
Capitalized manufacturing equipment for specific use	14,978	13,439
Construction in progress
Property, Plant and Equipment [Line Items]
Capitalized manufacturing equipment for specific use	$ 29,955	$ 19,942

Property, Plant, and Equipmen54

Property, Plant, and Equipment (Narrative) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Capitalized manufacturing equipment for specific use	$ 271,401	$ 254,419
Equipment | Primatene Mist
Property, Plant and Equipment [Line Items]
Capitalized manufacturing equipment for specific use	$ 2,600

Debt (Schedule of Debt) (Detail

Debt (Schedule of Debt) (Details) $ in Thousands, € in Millions	Sep. 30, 2016USD ($)	Sep. 30, 2016EUR (€)	Dec. 31, 2015USD ($)
Debt Instrument
Equipment under Capital Leases	$ 1,735		$ 802
Total debt and capital leases	42,704		41,099
Less current portion of long-term debt and capital leases	8,541		10,934
Long-term debt and capital leases, net of current portion	34,163		30,165
Mortgage Payable Matured January 2016 | East West Bank
Debt Instrument
Long Term Debt			3,725
Mortgage Payable Matured September 2016 | East West Bank
Debt Instrument
Long Term Debt			2,211
Equipment Loan - Due April 2017 | East West Bank
Debt Instrument
Long Term Debt	754		1,700
Equipment Loan - Due January 2019 | East West Bank
Debt Instrument
Long Term Debt	3,593		4,748
Mortgage Payable - Due February 2021 | East West Bank
Debt Instrument
Long Term Debt	3,679
Equipment Credit Line Due September 2021 | East West Bank
Debt Instrument
Long Term Debt	2,882
Mortgage Payable - Due October 2026 | East West Bank
Debt Instrument
Long Term Debt	3,591
Acquisition Loan - Due April 2019 | Cathay Bank
Debt Instrument
Long Term Debt	17,570		19,012
Mortgage Payable - Due April 2021 | Cathay Bank
Debt Instrument
Long Term Debt	4,391		4,460
French Government Loan - Due March 2018 | Seine-Normandie Water Agency
Debt Instrument
Long Term Debt	31		46
French Government Loan - Due June 2020 | Seine-Normandie Water Agency
Debt Instrument
Long Term Debt	104		128
French Government Loan - Due July 2021 | Seine-Normandie Water Agency
Debt Instrument
Long Term Debt	277		325
Note Payable To Merck
Debt Instrument
Long Term Debt	$ 4,097	€ 3.6	$ 3,942

Debt (Narrative) (Details)

Debt (Narrative) (Details) € in Millions	Jun. 01, 2014	Apr. 22, 2014USD ($)	Sep. 30, 2016USD ($)building	Mar. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2015EUR (€)	Jan. 31, 2015USD ($)item	Dec. 31, 2014USD ($)	Dec. 31, 2014EUR (€)	Apr. 30, 2014USD ($)	Jul. 31, 2013	Mar. 31, 2013USD ($)	Dec. 31, 2010USD ($)building	Sep. 30, 2016USD ($)building	Sep. 30, 2016EUR (€)building	Jan. 31, 2016USD ($)building	Jan. 31, 2015EUR (€)item	Apr. 30, 2014EUR (€)	Jul. 05, 2013USD ($)	Apr. 10, 2012USD ($)	Mar. 31, 2012USD ($)	Mar. 05, 2012USD ($)	Mar. 05, 2007USD ($)	Sep. 30, 2006USD ($)	Sep. 15, 2006USD ($)
Debt
Long-term Debt and Capital Lease Obligations			$ 34,163,000		$ 30,165,000									$ 34,163,000
Payment to Acquire Business, Gross														12,461,000
Equipment Loan - Due April 2017 | East West Bank
Debt
Principal amount												$ 4,900,000
Line of Credit Facility, Maximum Borrowing Capacity																						$ 8,000,000
Long Term Debt			754,000		1,700,000									754,000
Equipment Loan - Due April 2017 | East West Bank | Prime Rate
Debt
Debt Instrument, Basis Spread on Variable Rate												0.25%
Line of Credit Facility - Due September 2017 | East West Bank
Debt
Line of Credit Facility, Maximum Borrowing Capacity				$ 15,000,000																	$ 10,000,000
Line of Credit outstanding			0											0
Equipment Loan - Due January 2019 | East West Bank
Debt
Principal amount							$ 6,200,000
Debt Instrument, Interest Rate, Stated Percentage							4.48%										4.48%
Line of Credit Facility, Maximum Borrowing Capacity																			$ 8,000,000
Proceeds from borrowing under lines of credit							$ 6,200,000
Long Term Debt			$ 3,593,000		4,748,000									$ 3,593,000
Equipment Loan - Due January 2019 | East West Bank | Prime Rate
Debt
Debt Instrument, Basis Spread on Variable Rate											0.25%
Mortgage Payable - Due February 2021 | East West Bank
Debt
Principal amount													$ 4,500,000			$ 3,700,000
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid													$ 3,800,000			$ 3,300,000
Debt Instrument, Interest Rate, Stated Percentage			4.39%											4.39%	4.39%
Unrealized loss														$ 100,000
Long Term Debt			$ 3,679,000											3,679,000
Mortgage Payable - Due February 2021 | East West Bank | Rancho Cucamonga, California
Debt
Number of Buildings Securing Loan | building													1			1
Mortgage Payable - Due February 2021 | East West Bank | Chino, California
Debt
Number of Buildings Securing Loan | building													1
Equipment Credit Line Due September 2021 | East West Bank
Debt
Line of Credit Facility, Maximum Borrowing Capacity				$ 5,000,000
Line of Credit outstanding			2,900,000											2,900,000
Draw down period				18 months
Term of loan after draw down period expires				48 months
Long Term Debt			2,882,000											2,882,000
Mortgage Payable - Due October 2026 | East West Bank
Debt
Long Term Debt			3,591,000											3,591,000
Mortgage Payable - Due October 2026 | East West Bank | Rancho Cucamonga, California
Debt
Principal amount			3,600,000											3,600,000											$ 2,800,000
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid			$ 2,900,000											$ 2,900,000										$ 2,200,000
Number of Buildings Securing Loan | building			1											1	1
Debt Instrument, Interest Rate, Stated Percentage			4.15%											4.15%	4.15%
Unrealized loss														$ 100,000
Mortgage Payable - Due October 2026 | East West Bank | LIBOR | Rancho Cucamonga, California
Debt
Debt Instrument, Basis Spread on Variable Rate			2.75%											2.50%
Line of Credit Facility - Due May 2018 | Cathay Bank
Debt
Line of Credit Facility, Maximum Borrowing Capacity																				$ 20,000,000
Line of Credit outstanding			$ 0											$ 0
Acquisition Loan - Due April 2019 | Cathay Bank
Debt
Principal amount		$ 21,900,000
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid		$ 12,000,000
Debt Instrument, Term	120 months
Debt Instrument Loan Collateral Percentage		65.00%
Debt Instrument Covenant Period To Discharge Final Judgment														30 days
Long Term Debt			17,570,000		19,012,000									$ 17,570,000
Mortgage Payable - Due April 2021 | Cathay Bank
Debt
Principal amount										$ 4,600,000													$ 5,300,000
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid										$ 3,900,000
Debt Instrument, Interest Rate, Stated Percentage										5.42%								5.42%
Long Term Debt			4,391,000		4,460,000									4,391,000
French Government Loans | Seine-Normandie Water Agency
Debt
Principal amount							$ 700,000										€ 0.6
Number of Loans with Government Agency | item							3										3
Debt Instrument, Periodic Payment, Interest							$ 0
Notes Payable			400,000											400,000	€ 0.4
Note Payable To Merck
Debt
Principal amount										$ 16,000,000								€ 11.6
Debt Instrument, Term										4 years
Payment to Acquire Business, Gross					3,500,000	€ 3.2		$ 6,000,000	€ 4.9
Long Term Debt			4,097,000		3,942,000									4,097,000	€ 3.6
Equipment under Capital Leases
Debt
Capital Leased Assets, Gross			2,000,000		1,500,000									2,000,000
Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation			$ 100,000		$ 700,000									$ 100,000
Minimum | Equipment Loan - Due April 2017 | East West Bank
Debt
Debt Instrument, Interest Rate, Stated Percentage												3.50%
Minimum | Mortgage Payable - Due February 2021 | East West Bank | Prime Rate
Debt
Debt Instrument, Basis Spread on Variable Rate													5.00%
Minimum | Line of Credit Facility - Due May 2018 | Cathay Bank | Prime Rate
Debt
Debt Instrument, Interest Rate, Stated Percentage																				4.00%
Minimum | Acquisition Loan - Due April 2019 | Cathay Bank | Prime Rate
Debt
Debt Instrument, Basis Spread on Variable Rate		4.00%
Minimum | French Government Loans | Seine-Normandie Water Agency
Debt
Debt Instrument, Term							3 years
Minimum | French Government Loans | Seine-Normandie Water Agency | Prime Rate
Debt
Debt Instrument, Interest Rate, Stated Percentage			4.00%											4.00%	4.00%
Minimum | Note Payable To Merck
Debt
Debt Instrument, Interest Rate, Stated Percentage										3.00%								3.00%
Minimum | Note Payable To Merck | Prime Rate
Debt
Debt Instrument, Interest Rate, Stated Percentage			4.00%											4.00%	4.00%
Maximum | French Government Loans | Seine-Normandie Water Agency
Debt
Debt Instrument, Term							6 years

Income Taxes (Summary of the Co

Income Taxes (Summary of the Company's Income Tax Provision) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016
Income (loss) before taxes	$ 6,001	$ (4,276)	$ 19,569	$ (20,702)
Income tax expense (benefit)	2,111	(1,268)	6,295	(10,382)
Net income (loss)	$ 3,890	$ (3,008)	$ 13,274	$ (10,320)
Income tax expense (benefit) as a percentage of income (loss) before income taxes	35.20%	(29.70%)	32.20%	(50.10%)
Forecast
Income tax expense (benefit) as a percentage of income (loss) before income taxes					32.40%

Income Taxes (Valuation Allowan

Income Taxes (Valuation Allowance) (Details) € in Millions, $ in Millions	1 Months Ended		9 Months Ended
	Mar. 31, 2015USD ($)	Mar. 31, 2015EUR (€)	Sep. 30, 2016USD ($)	Dec. 31, 2015USD ($)	Apr. 30, 2014USD ($)	Apr. 30, 2014EUR (€)
Tax Credit Carryforward [Line Items]
Deferred Tax Assets, Valuation Allowance				$ 0.9
Increase to income tax expense due to losses in states from which the Company did not benefit from			$ 0.2
Intangible Deferred Tax Asset [Member]
Tax Credit Carryforward [Line Items]
Deferred Tax Assets, Valuation Allowance					$ 4.4	€ 3.2
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 3.3	€ 3.2

Stockholders' Equity (Summary o

Stockholders' Equity (Summary of the Changes in Stockholders' Equity) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Stockholders’ equity at the beginning of period			$ 295,510
Net loss	$ 3,890	$ (3,008)	13,274	$ (10,320)
Accumulated other comprehensive loss			(106)
Exercise of stock options			17,584
Issuance of common stock to employees under ESPP			915
Repurchase of common stock			(1,342)
Purchase of treasury stock			(8,986)
Stockholders’ equity at the end of period	$ 328,453		328,453
Nonemployee
Share-based compensation expense			1,122
Employee
Share-based compensation expense			$ 10,482

Stockholders' Equity (2014 Empl

Stockholders' Equity (2014 Employee Stock Purchase Plan) (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2014	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share base compensation		$ 3,555	$ 3,427	$ 11,604	$ 9,357
2014 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Stock Purchase Plan, Offering Duration, Maximum	27 months
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date	85.00%
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in Shares)				193,849
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)		1,806,151		1,806,151
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)	2,000,000
Allocated share base compensation		$ 100	$ 100	$ 400	$ 400

Stockholders' Equity (Share Buy

Stockholders' Equity (Share Buyback Program) (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016	Nov. 10, 2015	Nov. 06, 2014
Equity, Class of Treasury Stock [Line Items]
Treasury Stock, Value, Acquired, Cost Method		$ 8,986
November 2014 Share Repurchase Plan
Equity, Class of Treasury Stock [Line Items]
Stock buyback program, authorized amount			$ 10,000	$ 10,000
Treasury Stock, Shares, Acquired (in Shares)	46,333	710,833
Treasury Stock, Value, Acquired, Cost Method	$ 800	$ 9,000

Stockholders' Equity (The 2015

Stockholders' Equity (The 2015 Equity Incentive Plan) (Details) - The 2015 Equity Incentive Plan - shares	9 Months Ended
	Sep. 30, 2016	Mar. 18, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)	5,300,296
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)	3,938,687	5,000,000
Equity Incentive Plan, Term	10 years
Share Based Compensation Arrangement By Share Based Payment Award Potential Number of Additional Shares Authorized (in Shares)	3,000,000
Share Based Compensation Arrangement by Share Based Payment Award Potential Annual Increase in Shares, Percentage	2.50%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	1,129,962

Stockholders' Equity (Key Assum

Stockholders' Equity (Key Assumptions Used in Determining Fair Value of Options Granted) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Stockholders' Equity
Average volatility	31.90%	27.50%	30.40%	27.10%
Risk-free interest rate	1.30%	2.00%	1.50%	1.30%
Weighted-average expected life in years	6 years 3 months 18 days	6 years 3 months 18 days	5 years 6 months	4 years 6 months
Dividend yield rate	0.00%	0.00%	0.00%	0.00%

Stockholders' Equity (Summary64

Stockholders' Equity (Summary of Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Options
Outstanding Options, Beginning of period			12,240,467
Options granted			2,395,789
Options exercised			(1,262,020)
Options cancelled			(174,783)
Options expired			(245,538)
Outstanding Options, End of period	12,953,915		12,953,915
Exercisable at the end of period	8,183,715		8,183,715
Weighted-Average Exercise Price
Outstanding Exercise Price (in dollars per share)			$ 15.41
Options granted (in dollars per share)			12.19
Options exercised (in dollars per share)			13.93
Options cancelled (in dollars per share)			13.48
Options expired (in dollars per share)			23.84
Outstanding Exercise Price (in dollars per share)	$ 14.82		14.82
Exercisable at the end of period	$ 15.59		$ 15.59
Additional Disclosures
Outstanding Contractual Term (in Years)			4 years 6 months
Outstanding Intrinsic Value	$ 67,739		$ 67,739
Exercisable at the end of period (in Years)			2 years 11 months 27 days
Exercisable aggregate intrinsic value	41,704		$ 41,704
Allocated share base compensation	3,555	$ 3,427	11,604	$ 9,357
Employee Stock Option
Additional Disclosures
Allocated share base compensation	$ 1,900	$ 2,100	$ 6,700	$ 6,100

Stockholders' Equity (Informati

Stockholders' Equity (Information Relating to Option Grants and Exercises) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Stockholders' Equity
Weighted-average grant date fair value (in Dollars per share)	$ 6.34	$ 4.54	$ 3.42	$ 3.44
Intrinsic value of options exercised	$ 4,998	$ 268	$ 5,980	$ 2,721
Cash received	14,331	816	17,584	11,257
Total fair value of the options vested during the year	$ 2,688	$ 2,888	$ 7,948	$ 5,423

Stockholders' Equity (Summary66

Stockholders' Equity (Summary of Nonvested Options) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Options
Nonvested at beginning of period			5,202,095
Options granted			2,395,789
Options vested			(2,652,901)
Options forfeited			(174,783)
Nonvested at end of period	4,770,200		4,770,200
Weighted-Average Grant Date Fair Value
Nonvested at beginning of period (in dollars per share)			$ 3.44
Options granted (in dollars per share)	$ 6.34	$ 4.54	3.42	$ 3.44
Options vested (in dollars per share)			3
Options forfeited (in dollars per share)			4.67
Nonvested at end of period (in dollars per share)	$ 3.63		$ 3.63
Employee Consultant And Directors Stock Options
Weighted-Average Grant Date Fair Value
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 12.5		$ 12.5
Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			2 years 3 months 18 days

Stockholders' Equity (Restricte

Stockholders' Equity (Restricted Stock Units) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Contractual Term (in Years)			4 years 6 months
Allocated share base compensation	$ 3,555	$ 3,427	$ 11,604	$ 9,357
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			5 years
Allocated share base compensation	$ 1,500	$ 1,100	$ 4,500	$ 2,800
Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			2 years 4 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Restricted Stock Units, Number of Shares of Common Stock Per Award (in Shares)	1		1
Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options	$ 11,400		$ 11,400

Stockholders' Equity (Informa68

Stockholders' Equity (Information Relating to RSU Grants and Deliveries) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)shares
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Total RSUs outstanding at the beginning of the period	866,540
RSUs granted	732,021
RSUs forfeited	(53,157)
RSUs surrendered for taxes	(108,457)
Common stock delivered for RSUs	(218,875)
Total RSUs outstanding at the end of the period	1,218,072
Restricted Stock Units Issued as Compensation
Total Fair Market Value of RSUs Issued
RSUs granted (in Dollars) | $	$ 8,646

Stockholders' Equity (Equity Aw

Stockholders' Equity (Equity Awards to Consultants (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share base compensation	$ 3,555	$ 3,427	$ 11,604	$ 9,357
Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share base compensation		$ 100	$ 100	$ 100

Stockholders' Equity (Share-Bas

Stockholders' Equity (Share-Based Compensation Expense Included in the Statement of Operations) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share base compensation	$ 3,555	$ 3,427	$ 11,604	$ 9,357
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share base compensation	675	638	2,245	1,856
Selling, distribution and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share base compensation	45	49	176	148
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share base compensation	2,593	2,536	8,339	6,676
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share base compensation	$ 242	$ 204	$ 844	$ 677

Employee Benefits (Details)

Employee Benefits (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Employee Benefits
Defined Contribution Plan, Employer Matching Contribution, Percent of Match			50.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay			6.00%
Defined Contribution Plan, Employer Contribution Vesting Period			4 years
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0.3	$ 0.2	$ 0.7	$ 0.5
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	1.75%		1.75%		1.75%
Defined Benefit Plan, Benefit Obligation	$ 1.7		$ 1.7		$ 1.6
Pension Expense			$ 0.1	$ 0.1

Commitments and Contingencies (

Commitments and Contingencies (Distribution Agreement with Actavis, Inc) (Details) - Distribution Agreement - Actavis, Inc. - Enoxaparin - USD ($) $ in Millions	1 Months Ended
	Jan. 31, 2012	May 31, 2005	Jun. 30, 2016	Dec. 31, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from Customers		$ 4.5
Deferred Revenue	$ 4.5		$ 1.7	$ 2
Distribution Agreement With Corporate Partner, Renewal Option Period	3 years
Deferred Revenue, Period for Recognition	7 years

Commitments and Contingencies73

Commitments and Contingencies (Supply Agreement with MannKind Corporation) (Details) - MannKind Corporation - Supply Commitment - Recombinant Human Insulin (RHI) € in Millions, $ in Millions	Jul. 31, 2014USD ($)	Oct. 31, 2015USD ($)	Sep. 30, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2015EUR (€)	Sep. 30, 2016EUR (€)	Jul. 31, 2014EUR (€)
Supply Commitment [Line Items]
Supply commitment annual amount committed	$ 146				€ 27.1	€ 23.3	€ 120.1
Deferred Revenue	$ 14						€ 11
Long-term Supply Commitment, Optional Renewal Period	2 years
Sales			$ 6.8	$ 20.8	17.1
Unfulfilled commitment under the Supply Agreement | €					€ 6
Supply Commitment, Cancellation Fee | $		$ 0.8
Supply Agreement Renewal Notice Period	12 months
Termination notice period without cause	2 years
Termination notice period, change of regulatory approval	30 days
Payment period upon termination	60 days

Commitments and Contingencies74

Commitments and Contingencies (Collaboration Agreement) (Details) - Development agreement - Drug delivery system item in Millions, $ in Millions	9 Months Ended
	Sep. 30, 2016USD ($)item
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative Agreement, Upfront Payment	$ 0.5
Collaborative Agreement, Milestone Payments	0.7
Collaborative Agreement, Contingent Obligation	$ 1.3
Collaborative Agreement, Contingent Purchase Obligation First 12 Months, Units | item	1
Purchase period	12 months

Commitments and Contingencies75

Commitments and Contingencies (Operating Lease Agreements) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense	$ 0.8	$ 0.8	$ 2.5	$ 2.5
Minimum
Operating Leased Assets [Line Items]
Lessee Leasing Arrangements, Operating Leases, Renewal Term			1 year
Maximum
Operating Leased Assets [Line Items]
Lessee Leasing Arrangements, Operating Leases, Renewal Term			6 years

Commitments and Contingencies76

Commitments and Contingencies (Purchase Commitments) (Details) - USD ($) $ in Millions	1 Months Ended		9 Months Ended
	Nov. 30, 2012	Jan. 31, 2010	Sep. 30, 2016
Commitments to Purchase Equipment and Raw Materials
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Long-term Purchase Commitment, Amount			$ 17.9
Commitment to invest | ANP
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures			49
Contractual Obligation			61
Contractual Obligation, Due in Second Year			$ 12
Land-use rights | Commitment to invest
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Finite-lived Intangible Assets Acquired	$ 1.3	$ 1.2
Land-use rights | Commitment to develop land
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Contractual Obligation	$ 15

Litigation (Details)

Litigation (Details) $ in Millions	May 09, 2016USD ($)	May 04, 2016item	Apr. 07, 2015USD ($)	Sep. 21, 2011item	Oct. 31, 2011USD ($)
Enoxaparin Patent Litigation
Loss Contingencies [Line Items]
Fees and costs relating to a discovery motion	$ 0.4
False Claims Act Litigation
Loss Contingencies [Line Items]
Number of orders issued by district court | item		3
Eva Hernandez vs International Medication Systems Limited
Loss Contingencies [Line Items]
Litigation Settlement, Amount			$ 3.2
Pending Litigation [Member] | Enoxaparin Patent Litigation
Loss Contingencies [Line Items]
Number of Alleged Patent Infringements | item				2
Litigation, Plaintiff Preliminary Injunction Bond, Amount					$ 100.1

Subsequent Events (Details)

Subsequent Events (Details) $ in Millions	Nov. 07, 2016USD ($)
Subsequent Event
Subsequent Events
Increase authorized for share buyback program	$ 20